The UK Medical Eligibility Criteria (UKMEC) offer guidance on the contraindications for using contraception, including the combined oral contraceptive pill (COCP). The UKMEC categorizes the use of COCP as follows: no restriction (UKMEC1), advantages outweigh disadvantages (UKMEC2), disadvantages outweigh advantages (UKMEC3), and unacceptable risk (UKMEC4).

According to UKMEC3, COCP use may have more disadvantages than advantages for individuals who are over 35 years old and smoke less than 15 cigarettes per day, have a BMI over 35, experience migraines without aura, have a family history of deep vein thrombosis or pulmonary embolism in a first-degree relative under 45 years old, have controlled hypertension, are immobile (e.g., use a wheelchair), or are breastfeeding and between 6 weeks to 6 months postpartum.

On the other hand, UKMEC4 indicates that COCP use poses an unacceptable risk for individuals who are over 35 years old and smoke more than 15 cigarettes per day, experience migraines with aura, have a personal history of deep vein thrombosis or pulmonary embolism, have a personal history of stroke or ischemic heart disease, have uncontrolled hypertension, have breast cancer, have recently undergone major surgery with prolonged immobilization, or are breastfeeding and less than 6 weeks postpartum.

Source: FSRH UKMEC for contraceptive use.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

If the 2nd repeat smear at 24 months shows a negative result for high-risk human papillomavirus (hrHPV), the patient can return to routine recall for cervical cancer screening. Since the patient is over 50 years old, a smear test should be taken every 5 years as part of routine recall. It is not necessary to perform a cytology swab or refer the patient to colposcopy as a negative HPV result does not indicate the presence of cervical cancer. Additionally, repeating the HPV test in 3 years is not necessary for this patient as it is only the routine recall protocol for patients aged 25-49.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The correct course of action for an individual who tests positive for high-risk human papillomavirus (hrHPV) but receives a negative cytology report during routine primary HPV screening is to repeat the HPV test after 12 months. If the HPV test is negative at this point, the individual can return to routine recall. However, if the individual remains hrHPV positive and cytology negative, another HPV test should be conducted after a further 12 months. If the individual is still hrHPV positive after 24 months, they should be referred to colposcopy. It is incorrect to repeat the cervical smear in 3 months, wait 3 years for a repeat smear, or refer the individual to colposcopy without abnormal cytology.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

If a patient’s cervical smear shows abnormal cytology and a positive result for a high-risk strain of human papillomavirus, the next step is to refer them for colposcopy to obtain a cervical biopsy and assess for cervical cancer. This patient cannot be discharged to normal recall as they are at significant risk of developing cervical cancer. If the cytology is inadequate, it can be retested in 3 months. However, if the cytology shows low-grade dyskaryosis, colposcopy and further assessment are necessary. Delaying the repeat cytology for 6 months would not be appropriate. If the cytology is normal but the patient is positive for high-risk human papillomavirus, retesting for human papillomavirus in 12 months is appropriate. However, if abnormal cytology is present with high-risk human papillomavirus, colposcopy and further assessment are needed.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hr HPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The diagnosis of vaginal candidiasis does not require a high vaginal swab if the symptoms are highly suggestive. In fact, the diagnosis can be made clinically based on the patient’s symptoms. For example, if a patient presents with thickened, white discharge that resembles cottage cheese and vaginal itching, along with a normal vaginal pH, it is very likely that they have vaginal candidiasis. It is important to note that glycated haemoglobin (HbA1c) is not necessary for diagnosis unless the patient has recurrent episodes of vaginal candidiasis, which may indicate diabetes mellitus. Additionally, a midstream urine sample is not useful in diagnosing vaginal candidiasis and should only be used if a sexually-transmitted infection is suspected.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

If one COCP pill is missed, the individual should take the missed pill as soon as possible, but no further action is necessary. They should also take the next pill at the usual time, even if that means taking two pills in one day. Emergency contraception is not required in this situation, as only one pill was missed. However, if two or more pills are missed in week 3 of a packet, it is recommended to omit the pill-free interval and use barrier contraception for 7 days.

Missed Pills in Combined Oral Contraceptive Pill

When taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol, it is important to know what to do if a pill is missed. The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their recommendations in recent years. If one pill is missed at any time in the cycle, the woman should take the last pill even if it means taking two pills in one day and then continue taking pills daily, one each day. No additional contraceptive protection is needed in this case.

However, if two or more pills are missed, the woman should take the last pill even if it means taking two pills in one day, leave any earlier missed pills, and then continue taking pills daily, one each day. In this case, the woman should use condoms or abstain from sex until she has taken pills for 7 days in a row. If pills are missed in week 1 (Days 1-7), emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week 1. If pills are missed in week 2 (Days 8-14), after seven consecutive days of taking the COC there is no need for emergency contraception.

If pills are missed in week 3 (Days 15-21), the woman should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of 7 days on, 7 days off. It is important to follow these guidelines to ensure the effectiveness of the COC in preventing pregnancy.

Sacrocolpopexy is the recommended treatment for vaginal vault prolapse. This surgical procedure involves suspending the vaginal apex to the sacral promontory, typically using the uterosacral ligaments for support. Other surgical options include anterior colporrhaphy for repairing a cystocele, vaginoplasty for reconstructing the vagina, vaginal hysterectomy for removing the uterus via the vagina, and bilateral oophorectomy for removing the ovaries. However, these options would not be appropriate for treating vaginal vault prolapse as the ovaries are not involved in the underlying pathology.

Understanding Urogenital Prolapse

Urogenital prolapse is a condition where one of the pelvic organs descends, causing protrusion on the vaginal walls. This condition is prevalent among postmenopausal women, affecting around 40% of them. There are different types of urogenital prolapse, including cystocele, cystourethrocele, rectocele, uterine prolapse, urethrocele, and enterocele.

Several factors increase the risk of developing urogenital prolapse, such as increasing age, vaginal deliveries, obesity, and spina bifida. The condition presents with symptoms such as pressure, heaviness, and a sensation of bearing down. Urinary symptoms such as incontinence, frequency, and urgency may also occur.

Treatment for urogenital prolapse depends on the severity of the condition. If the prolapse is mild and asymptomatic, no treatment may be necessary. Conservative treatment options include weight loss and pelvic floor muscle exercises. A ring pessary may also be used. In severe cases, surgery may be required. The surgical options for cystocele/cystourethrocele include anterior colporrhaphy and colposuspension. Uterine prolapse may require hysterectomy or sacrohysteropexy, while posterior colporrhaphy is used for rectocele.

In conclusion, urogenital prolapse is a common condition among postmenopausal women. It is important to understand the different types, risk factors, and treatment options available to manage the condition effectively.

Women who have taken ulipristal acetate should wait for 5 days before starting regular hormonal contraception. This is because ulipristal may reduce the effectiveness of hormonal contraception. The same advice should be given for other hormonal contraception methods such as the pill, patch, or ring. Barrier methods should be used before the effectiveness of the COCP can be assured. If the patient is starting the COCP within the first 5 days of her cycle, barrier methods may not be necessary. However, in this case, barrier methods are required. The patient can be prescribed the COCP if it is her preferred method of contraception. There is no need to wait until the start of the next cycle before taking the pill, as long as barrier methods are used for 7 days.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

The Most Appropriate Initial Investigation for Amenorrhoea: Urine Pregnancy Test

When a patient presents with amenorrhoea, the most appropriate initial investigation is always a pregnancy test. If pregnancy is excluded, further investigations may be necessary to determine the underlying cause. For example, a diagnosis of polycystic ovary syndrome (PCOS) may be supported by high levels of free testosterone with low levels of sex-hormone binding globulin, which can be tested after excluding pregnancy. A pelvic ultrasound is also a useful investigation for PCOS and should be done following β-HCG estimation. While a raised LH: FSH ratio may be suggestive of PCOS, it is not diagnostic and not the initial investigation of choice here. Similarly, an oral glucose tolerance test might be useful in patients diagnosed with PCOS, but it would not be an appropriate initial investigation. Therefore, a urine pregnancy test is the most important first step in investigating amenorrhoea.

The addition of progesterone to HRT increases the likelihood of developing breast cancer, but this risk is dependent on the duration of treatment and decreases after HRT is discontinued. However, it does not affect the risk of dying from breast cancer. HRT with only oestrogen is linked to a lower risk of coronary heart disease, while combined HRT has a minimal or no impact on CHD risk. progesterone-only HRT is not available. NICE does not provide a specific risk assessment for ovarian cancer in women taking HRT, but refers to a meta-analysis indicating an increased risk for both oestrogen-only and combined HRT preparations.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

In cases where delayed placental delivery is observed in patients with placenta accreta, hysterectomy is the recommended treatment. This patient has a history of previous caesarean-section and pelvic inflammatory disease, indicating a likely placenta accreta, which was also diagnosed antenatally on ultrasound. The optimal management approach involves leaving the placenta in-situ and performing a hysterectomy to avoid potential haemorrhage from attempts to actively remove the placenta. While medical management with oxytocin and ergometrine may help manage post-partum haemorrhage, it is not a definitive treatment option. Cord traction is also unlikely to be effective as the placenta is abnormally implanted into the uterine wall. Waiting another 30 minutes is not advisable due to the risk of further bleeding.

Understanding Placenta Accreta

Placenta accreta is a condition where the placenta attaches to the myometrium instead of the decidua basalis, which can lead to postpartum hemorrhage. This condition is caused by a defective decidua basalis. There are three types of placenta accreta, which are categorized based on the degree of invasion. The first type is accreta, where the chorionic villi attach to the myometrium. The second type is increta, where the chorionic villi invade into the myometrium. The third type is percreta, where the chorionic villi invade through the perimetrium.

There are certain risk factors that increase the likelihood of developing placenta accreta, such as having a previous caesarean section or placenta previa. It is important for healthcare providers to be aware of these risk factors and monitor patients closely during pregnancy and delivery. Early detection and management of placenta accreta can help prevent complications and ensure the best possible outcome for both the mother and baby.

Understanding Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. It is characterized by menstrual irregularities, signs of hyperandrogenism, and ultrasonographic evidence of polycystic ovaries. The Rotterdam criteria provide diagnostic criteria for PCOS, which include oligomenorrhoea or amenorrhoea, clinical or biochemical signs of hyperandrogenism, and ultrasonographic evidence of polycystic ovaries.

Follicle counts and ovarian volume are important ultrasonographic features used to diagnose PCOS. At least 12 follicles in one ovary, measuring 2-9 mm in diameter, and an ovarian volume of >10 ml are diagnostic of PCOS. However, the absence of these features does not exclude the diagnosis if two of the three criteria are met.

Total testosterone levels are usually raised in PCOS, while FSH is usually within the normal range or low, and LH is raised. The ratio of LH:FSH is usually >3:1 in PCOS.

A single complex cyst in one ovary is an abnormal finding and requires referral to a gynaecology team for further assessment.

Understanding the Diagnostic Criteria and Ultrasonographic Features of PCOS

The current guidelines for cervical cancer screening recommend using hrHPV as the first screening test. If the result is negative, the patient can return to routine recall. However, if the result is positive, the sample is examined for cytology. If the cytology is normal, the patient is asked to return for screening in 12 months instead of the usual 3 years. If the hrHPV result is negative at the 12-month follow-up, the patient can return to routine recall. But if the result is positive again, as in this scenario, and the cytology is normal, the patient should attend another screening in 12 months. If the cytology is abnormal at any point, the patient should be referred for colposcopy. If the patient attends a third screening in another 12 months and the hrHPV result is still positive, she should be referred for colposcopy regardless of the cytology result.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Condoms act as a barrier contraceptive and do not have any impact on ovulation, therefore they do not cause any delay in fertility. The intrauterine system (IUS) functions by thickening cervical mucous and may prevent ovulation in some women, but most women still ovulate. Once the IUS is removed, most women regain their fertility immediately.

The combined oral contraceptive pill may postpone the return to a normal menstrual cycle in some women, but the majority of them can conceive within a month of discontinuing it. The progesterone-only pill is less likely to delay the return to a normal cycle as it does not contain oestrogen.

Depo-Provera can last up to 12 weeks, and it may take several months for the body to return to a normal menstrual cycle, which can delay fertility. As a result, it is not the most suitable method for a woman who wants to resume ovulatory cycles immediately.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

The appropriate management for urgency urinary incontinence (UUI) is to refer the patient for bladder training. UUI is characterized by uncontrollable bladder leakage that occurs shortly after the patient experiences a sudden urge to urinate, and is often associated with an overactive bladder that causes symptoms such as increased urinary frequency and nocturia. Advising the patient to reduce fluid intake and use continence products is not the correct approach, as both too much and too little fluid can contribute to lower urinary tract symptoms. Instead, patients should be advised to make lifestyle changes such as reducing caffeine intake, losing weight, and quitting smoking. Referring the patient for pelvic floor muscle training is the appropriate management for stress incontinence, which causes urine leakage during exertion, sneezing, or coughing. However, this is not applicable in this case as the patient denies these symptoms. If conservative management is unsuccessful and the patient does not wish to explore surgical options, a trial treatment with duloxetine may be considered for stress incontinence.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

Contraception for Obese Patients

Obesity is a risk factor for venous thromboembolism in women taking the combined oral contraceptive pill (COCP). To minimize this risk, the UK Medical Eligibility Criteria (UKMEC) recommends that women with a body mass index (BMI) of 30-34 kg/m² should use the COCP with caution (UKMEC 2), while those with a BMI of 35 kg/m² or higher should avoid it altogether (UKMEC 3). Additionally, the effectiveness of the combined contraceptive transdermal patch may be reduced in patients weighing over 90kg.

Fortunately, there are other contraceptive options available for obese patients. All other methods of contraception have a UKMEC of 1, meaning they are considered safe and effective for most women, regardless of their weight. However, it’s important to note that patients who have undergone gastric sleeve, bypass, or duodenal switch surgery cannot use oral contraception, including emergency contraception, due to the lack of efficacy.

In summary, obese patients should be aware of the increased risk of venous thromboembolism associated with the COCP and consider alternative contraceptive options. It’s important to discuss these options with a healthcare provider to determine the best choice for each individual patient.

Understanding Risk Factors for Ectopic Pregnancy

Ectopic pregnancy is a serious condition where a fertilized egg implants outside of the uterus, usually in the fallopian tube. While there are several risk factors associated with ectopic pregnancy, some common misconceptions exist. Here are some important facts to keep in mind:

Methods of contraception, such as intrauterine devices (IUDs), do not increase the risk of ectopic pregnancy. However, IUDs can cause side effects such as irregular bleeding and pelvic pain.

The combined oral contraceptive pill can cause various side effects, but ectopic pregnancy is not one of them.

Subserosal fibroids and corpus luteal cysts can cause abdominal pain and other symptoms, but they do not increase the risk of ectopic pregnancy.

Previous miscarriage is not a risk factor for ectopic pregnancy, but it can increase the risk of future miscarriages.

It’s important to understand the true risk factors for ectopic pregnancy in order to make informed decisions about contraception and reproductive health. If you experience symptoms such as abdominal pain, vaginal bleeding, or shoulder pain, seek medical attention immediately as these could be signs of ectopic pregnancy.

During the initial 6 months after the intrauterine system is inserted, experiencing irregular bleeding is a typical adverse effect. However, over time, the majority of women who use the IUS will experience reduced or absent menstrual periods, which is advantageous for those who experience heavy menstrual bleeding or prefer not to have periods.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucous. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

If pelvic floor muscle exercises are ineffective and surgical intervention is not desired, duloxetine may be used to manage stress incontinence, as per NICE guidance from 2019. It should be noted that bladder retraining is not recommended for this type of incontinence, and oxybutynin is only indicated for urge incontinence if bladder retraining has failed. Referral for urodynamics testing is also not recommended, with urogynaecology being the preferred option for secondary care. Additionally, NICE does not recommend continuing pelvic floor exercises for an additional 3 months.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

When dealing with patients who have urinary incontinence, it is crucial to eliminate the possibility of a UTI and diabetes mellitus as underlying causes. The first step in investigating urinary incontinence would be to conduct a urine dipstick and culture test, which can be easily done in a GP’s office. Other initial investigations include keeping a bladder diary for at least three days and undergoing urodynamic studies. It is important to note that the reliability of urine dip tests is questionable in women over 65 years of age and those who have catheters. A three-day bladder diary is necessary for initial investigations, and a one-day diary would not suffice. CT scans are not typically used to investigate urinary incontinence but are useful in detecting renal pathology such as ureteric calculi. Cystoscopy is not appropriate for this patient and is usually reserved for cases where bladder cancer is suspected.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

Differential diagnosis of abdominal symptoms

Abdominal symptoms can have various causes, and a careful differential diagnosis is necessary to identify the underlying condition. In this case, the patient presents with bloating, early satiety, urinary symptoms, and an elevated CA-125 level. Here are some possible explanations for these symptoms, based on their typical features and diagnostic markers.

Ovarian cancer: This is a possible diagnosis, given the mass effect on the gastrointestinal and urinary organs, as well as the elevated CA-125 level. However, ovarian cancer often presents with vague symptoms initially, and other conditions can also increase CA-125 levels. Anorexia and weight loss are additional symptoms to consider.

Colorectal cancer: This is less likely, given the absence of typical symptoms such as change in bowel habits, rectal bleeding, or anemia. The classical marker for colorectal cancer is CEA, not CA-125.

Irritable bowel syndrome: This is also less likely, given the age of the patient and the presence of urinary symptoms. Irritable bowel syndrome is a diagnosis of exclusion, and other likely conditions should be ruled out first.

Genitourinary prolapse: This is a possible diagnosis, given the urinary symptoms and the sensation of bulging or fullness. Vaginal spotting, pain, or irritation are additional symptoms to consider. However, abdominal bloating and early satiety are not typical, and CA-125 levels should not be affected.

Diverticulosis: This is unlikely, given the absence of typical symptoms such as altered bowel habits or left iliac fossa pain. Diverticulitis can cause rectal bleeding, but fever and acute onset of pain are more characteristic.

In summary, the differential diagnosis of abdominal symptoms should take into account the patient’s age, gender, medical history, and specific features of the symptoms. Additional tests and imaging may be necessary to confirm or exclude certain conditions.

The menopause is diagnosed retrospectively and occurs 12 months after the last menstrual period. Women who experience menopause before the age of 50 need contraception for at least 2 years after their last menstrual period, while those over 50 require only 1 year of contraception. Therefore, it would be incorrect to assume that this woman does not need contraception because she is protected. Prescribing the COCP for only 12 months would also be inappropriate, especially since she is a smoker over the age of 35. Hormone replacement therapy should not be used as a sole form of contraception, and barrier methods are less effective than other types of contraception. The most appropriate option is the IUS, which can be used for 7 years (off-licence) or 2 years after her last menstrual period and will take her through menopause. This information is based on the FSRH’s guidelines on contraception for women aged over 40 (July 2010).

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

According to NICE guidelines, an endometrial biopsy should be performed if necessary to rule out endometrial cancer or atypical hyperplasia. The biopsy is recommended for women who experience persistent intermenstrual bleeding and for those aged 45 and above who have had unsuccessful or ineffective treatment. In the case of the patient mentioned above, her treatment has not been successful and she has a thickened endometrium. Although there is some debate about the thickness of the endometrium in premenopausal women, this patient qualifies for a biopsy based on her failed medical treatment alone, making it the most appropriate option.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Even if a child is Gillick competent, they are still unable to consent to sexual intercourse if they are under the age of 13. Therefore, any interaction with this age group should prompt child protection measures to be taken. Simply prescribing medication or ignoring the situation would not be in compliance with this protocol.

When it comes to providing contraception to young people, there are legal and ethical considerations to take into account. In the UK, the age of consent for sexual activity is 16 years, but practitioners may still offer advice and contraception to young people they deem competent. The Fraser Guidelines are often used to assess a young person’s competence. Children under the age of 13 are considered unable to consent to sexual intercourse, and consultations regarding this age group should trigger child protection measures automatically.

It’s important to advise young people to have STI tests 2 and 12 weeks after an incident of unprotected sexual intercourse. Long-acting reversible contraceptive methods (LARCs) are often the best choice for young people, as they may be less reliable in remembering to take medication. However, there are concerns about the effect of progesterone-only injections (Depo-provera) on bone mineral density, and the UKMEC category of the IUS and IUD is 2 for women under the age of 20 years, meaning they may not be the best choice. The progesterone-only implant (Nexplanon) is therefore the LARC of choice for young people.

Contraception and Treatment for Menorrhagia

When a woman is experiencing problematical menorrhagia and needs contraception, it is recommended to use progesterone-based long-acting reversible contraception over progesterone-only or combined-oral contraceptive pills due to its higher efficacy in preventing pregnancy. While tranexamic acid may help reduce menorrhagia, it is not a contraceptive. Mefenamic acid is more effective in providing analgesia than in treating menorrhagia and is also not a contraceptive.

The most appropriate therapy for this situation would be Mirena, which is expected to provide good contraception while also potentially leading to amenorrhoea in the majority of cases. It is important to consider both contraception and treatment for menorrhagia in order to provide comprehensive care for women experiencing these issues. These recommendations are based on the FSRH guidelines on contraception from July 2019.

When it is necessary to stop breastfeeding, Cabergoline is the preferred medication for suppressing lactation. This is because Cabergoline is a dopamine receptor agonist that can inhibit the production of prolactin, which in turn suppresses lactation. It should be noted that Norethisterone has no effect on lactation, Misoprostol is used to soften the cervix during labor induction, and Ursodeoxycholic acid is a bile acid chelating agent used to treat cholestasis in pregnancy.

Techniques for Suppressing Lactation during Breastfeeding

Breastfeeding is a natural process that provides essential nutrients to newborns. However, there may be situations where a mother needs to suppress lactation. This can be achieved by stopping the lactation reflex, which involves stopping suckling or expressing milk. Additionally, supportive measures such as wearing a well-supported bra and taking analgesia can help alleviate discomfort. In some cases, medication may be required, and cabergoline is the preferred choice. By following these techniques, lactation can be suppressed effectively and safely.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

In cases of recurrent vaginal candidiasis, it is recommended to consider a blood test to rule out diabetes as a potential underlying condition. Other predisposing factors such as immunosuppression, pregnancy, and antibiotic or steroid usage should also be evaluated. While HIV testing is important, a CD4+ T-cell count is not the first line investigation and HIV testing is typically done using antibody, antigen, or nucleotide testing. A full blood count may be useful to assess the patient’s general health, but it is not the most likely cause of recurrent vaginal candidiasis. HbA1c testing should be done to assess for diabetes mellitus, and a pregnancy test and HIV test may also be indicated. While a high vaginal swab can confirm the diagnosis, it will not provide information about any underlying diseases.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

If a cervical cancer screening sample is positive for high-risk strains of human papillomavirus (hrHPV) but shows no cytological abnormalities, the recommended course of action is to repeat the smear after 12 months. This is in accordance with current guidance. Colposcopy is not necessary in this case. Repeating the smear after 3 months or waiting 3 years for routine recall are also not appropriate. A repeat smear after 6 months would only be necessary after treatment for cervical intraepithelial neoplasia.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Common Causes of Abnormal Uterine Bleeding in Young Women

Abnormal uterine bleeding is a common problem among young women, especially within the first years of menarche. There are several possible causes, including anovulatory dysfunctional uterine bleeding, cervical cancer, ovulatory dysfunctional uterine bleeding, submucosal leiomyoma, and prolactinoma.

Anovulatory dysfunctional uterine bleeding occurs when the hormonal axis that regulates the menstrual cycle is not fully matured. This can lead to irregular and unpredictable bleeding due to the lack of ovulation and the resulting hyperoestrogenic state that induces endometrial hyperplasia.

Cervical cancer is associated with human papillomavirus infection and other risk factors such as smoking, early intercourse, multiple sexual partners, oral contraceptive use, and immunosuppression. It can cause vaginal spotting, post-coital bleeding, dyspareunia, and vaginal discharge.

Ovulatory dysfunctional uterine bleeding is caused by excessive production of vasoconstrictive prostaglandins in the endometrium during a menstrual period. This can result in more severe and prolonged bleeding associated with painful uterine contractions.

Submucosal leiomyoma is a benign neoplastic mass that protrudes into the intrauterine cavity and can cause metrorrhagia or menorrhagia. It is rare in young women.

Prolactinoma can result in oligomenorrhoea/amenorrhoea or anovulation and metromenorrhagia by inhibiting the action of hypothalamic gonadotrophin-releasing hormone on the anterior pituitary gland. This leads to reduced follicle-stimulating hormone and luteinising hormone secretion, resulting in abnormal uterine bleeding.

In conclusion, abnormal uterine bleeding in young women can have various causes, and a proper diagnosis is essential for appropriate treatment. Anovulatory dysfunctional uterine bleeding is the most likely cause in this case due to the patient’s age.

If an 18-year-old woman is suspected to be a victim of female genital mutilation (FGM), the best course of action is to report the incident to the police as FGM is illegal in the UK. Contacting the medical director or providing the patient with self-referral pathway information are not appropriate responses. It is important to acknowledge the patient’s wishes, but due to her age, reporting the incident to the police is necessary for investigation.

Understanding Female Genital Mutilation

Female genital mutilation (FGM) is a term used to describe any procedure that involves the partial or complete removal of the external female genitalia or any other injury to the female genital organs for non-medical reasons. The World Health Organization (WHO) has classified FGM into four types. Type 1 involves the partial or total removal of the clitoris and/or the prepuce, while type 2 involves the partial or total removal of the clitoris and the labia minora, with or without excision of the labia majora. Type 3 involves the narrowing of the vaginal orifice with the creation of a covering seal by cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris. Finally, type 4 includes all other harmful procedures to the female genitalia for non-medical purposes, such as pricking, piercing, incising, scraping, and cauterization. It is important to understand the different types of FGM to raise awareness and prevent this harmful practice.

The luteal phase of the menstrual cycle remains constant at 14 days, while the follicular phase can vary. The serum progesterone level reaches its peak 7 days after ovulation. For a 35-day cycle, the follicular phase would be 21 days (with ovulation occurring on day 21) and the luteal phase would be 14 days, resulting in the progesterone level peaking on day 28 (35-7). However, relying on day 21 progesterone levels would only be useful for women with a regular menstrual cycle of 28 days. While basal body temperature charting can be used to track ovulation, it is not the recommended method by NICE. An increase in basal temperature after ovulation can indicate successful ovulation.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

The addition of progesterone to hormone replacement therapy (HRT) has been linked to an increased risk of breast cancer, as well as venous thromboembolism and cardiovascular disease. HRT may be recommended for menopausal patients experiencing vasomotor symptoms such as hot flashes, night sweats, and palpitations. However, if a patient only presents with urogenital symptoms, topical oestrogens such as oestradiol creams or pessaries may be more appropriate. These act locally to alleviate vaginal dryness, reduce UTI recurrence, and ease dyspareunia. For patients with vasomotor symptoms, HRT preparations with systemic effects (such as oral medications, topical patches, and implants) may be considered. If the patient has not undergone a hysterectomy, their HRT regime must include both oestrogen and progesterone to prevent hypertrophy of the uterus and a 5-10x increased risk of endometrial carcinoma associated with unopposed oestrogen therapy.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Contraceptive Options for Patients with Uterine Fibroids and Carbamazepine Use

Patients with uterine fibroids and concurrent use of carbamazepine may have limited contraceptive options due to drug interactions and uterine cavity distortion. The progesterone-only injectable is a suitable option as it does not interact with enzyme inducers and is not affected by uterine cavity distortion. The copper intrauterine device and levonorgestrel-releasing intrauterine system are not recommended in this case. The progesterone-only implant and combined oral contraceptive pill have severe interactions with carbamazepine, reducing their efficacy. It is important to consider individual patient factors and discuss all available contraceptive options with them.

Polycystic ovarian syndrome patients commonly experience insulin resistance, which can result in complex alterations in the hypothalamic-pituitary-ovarian axis.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is associated with high levels of luteinizing hormone and hyperinsulinemia. Management of PCOS is complex and varies depending on the individual’s symptoms. Weight reduction is often recommended, and a combined oral contraceptive pill may be used to regulate menstrual cycles and manage hirsutism and acne. If these symptoms do not respond to the pill, topical eflornithine or medications like spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another common issue associated with PCOS. Weight reduction is recommended, and the management of infertility should be supervised by a specialist. There is ongoing debate about the most effective treatment for infertility in patients with PCOS. Clomiphene is often used, but there is a potential risk of multiple pregnancies with anti-oestrogen therapies like Clomiphene. Metformin is also used, either alone or in combination with Clomiphene, particularly in patients who are obese. Gonadotrophins may also be used to stimulate ovulation. The Royal College of Obstetricians and Gynaecologists (RCOG) published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS.

According to the BNF, the copper intra-uterine device is the most efficient option for emergency contraception and should be offered to all eligible women seeking such services. Unlike other medications, its effectiveness is not influenced by BMI. Additionally, it provides long-term contraception, which is an added advantage for the patient. If the copper intra-uterine device is not appropriate or acceptable to the patient, oral hormonal emergency contraception should be offered. However, the effectiveness of these contraceptives is reduced in patients with a high BMI. A double dose of levonorgestrel is recommended for patients with a BMI of over 26 kg/m² or body weight greater than 70kg. It is unclear which of the two oral hormonal contraceptives is more effective for patients with a raised BMI. The levonorgestrel intrauterine system and ethinylestradiol with levonorgestrel are not suitable for emergency contraception. In conclusion, the copper intrauterine device is the most effective method for this patient because it is not affected by BMI, unlike oral hormonal emergency contraceptives.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

The use of the levonorgestrel IUS as a contraceptive or treatment for menorrhagia is not recommended in women with a distorted fibroid uterus due to the complexity and difficulty of the procedure. Other contraindications include current pregnancy, pelvic inflammatory disease, trophoblastic disease, breast/endometrial/ovarian/cervical cancer, postpartum endometritis, septic abortion/miscarriage in the last three months, and cervical intra-epithelial neoplasia. Migraine with aura is an absolute contraindication to the use of the combined oral contraceptive pill, but the levonorgestrel IUS can be safely used. It is safe to use the levonorgestrel IUS during breastfeeding, and it can be used by women of all ages, regardless of parity. A history of venous thromboembolism is a contraindication to the use of the combined oral contraceptive pill, but the levonorgestrel IUS is safe to use according to NICE guidance.

Understanding Hormonal Patterns in Hypogonadism: A Guide to Diagnosis

Hypogonadism is a condition that affects the production of hormones necessary for sexual development. One form of hypogonadism is Kallmann syndrome, which is characterized by delayed or absent puberty and an inability to smell. This condition is caused by a defect in the release or action of gonadotropin-releasing hormone (GnRH), leading to gonadal failure. As a result, we expect to see reduced levels of GnRH, luteinising hormone (LH), follicle-stimulating hormone (FSH), and oestrogen in affected individuals.

Secondary hypogonadism, on the other hand, is caused by a problem in the pituitary gland. This can result in increased levels of GnRH, but decreased levels of LH, FSH, and oestrogen.

Primary hypogonadism, such as in Klinefelter’s and Turner syndrome, is characterized by problems with the gonads. In these cases, we expect to see increased levels of GnRH, LH, and FSH, but decreased levels of oestrogen.

Ectopic or unregulated oestrogen production can also cause hormonal imbalances, leading to decreased levels of GnRH, LH, and FSH, but increased levels of oestrogen.

It is important to understand these hormonal patterns in order to diagnose and treat hypogonadism effectively. By identifying the underlying cause of the condition, healthcare professionals can provide appropriate interventions to improve sexual development and overall health.

If a cervical smear test is hrHPV positive but cytologically normal, the recommended course of action is to repeat the test in 12 months. This is in contrast to negative hrHPV results, which are returned to normal recall. Abnormal cytology results require colposcopy, but normal cytology results do not. It is important to note that returning to normal recall is not appropriate in this case, as the patient’s higher risk status warrants a repeat test sooner than the standard 3-year interval. Repeating the test within 3 or 6 months is also not recommended.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Differential Diagnosis for Secondary Amenorrhoea: Polycystic Ovary Syndrome, Cushing’s Syndrome, Primary Ovarian Failure, Hypothalamic Disease, and Adrenal Tumour

Secondary amenorrhoea, the cessation of menstruation after previously menstruating, can have various causes. In a patient who is overweight, has acne, and slightly elevated testosterone and LH levels, polycystic ovary syndrome (PCOS) is a likely diagnosis. PCOS is characterized by small cysts in the ovaries and is linked to insulin resistance, hypertension, lipid abnormalities, and increased risk for cardiovascular disease. Hirsutism is also common in PCOS.

Cushing’s syndrome is a potential differential diagnosis for this patient, but blood results would show suppression of LH and FSH, not elevation. Primary ovarian failure is much rarer than PCOS and would show elevated serum FSH levels. Hypothalamic disease is less likely in this patient with multiple risk factors for PCOS, as it would result in decreased production of gonadotropin-releasing hormone and lower than normal detectable serum levels of LH and FSH. An adrenal tumour, particularly an adenoma, could rarely lead to amenorrhoea, but would also present with other symptoms such as palpitations and weight loss. Other adrenal tumours that secrete sex hormones are even rarer and would also be associated with weight loss.

A labial lump and inguinal lymphadenopathy in an older woman may indicate the presence of vulval carcinoma, as these symptoms are concerning and should not be ignored. Although labial lumps are not uncommon, it is important to be vigilant and seek medical attention if a new lump appears.

Understanding Vulval Carcinoma

Vulval carcinoma is a type of cancer that affects the vulva, which is the external female genitalia. It is a relatively rare condition, with only around 1,200 cases diagnosed in the UK each year. The majority of cases occur in women over the age of 65 years, and around 80% of cases are squamous cell carcinomas.

There are several risk factors associated with vulval carcinoma, including human papillomavirus (HPV) infection, vulval intraepithelial neoplasia (VIN), immunosuppression, and lichen sclerosus. Symptoms of vulval carcinoma may include a lump or ulcer on the labia majora, inguinal lymphadenopathy, and itching or irritation.

It is important for women to be aware of the risk factors and symptoms of vulval carcinoma, and to seek medical attention if they experience any concerning symptoms. Early detection and treatment can improve outcomes and increase the chances of a full recovery.

Endometriosis is characterized by pelvic pain, dysmenorrhoea, dyspareunia, and subfertility. The symptoms experienced by the patient in this case suggest the presence of intra-pelvic pathology, including a retroverted uterus and age-related factors. Chlamydia infection is often asymptomatic and does not typically cause dysmenorrhoea, although dyspareunia may occur. Lower abdominal pain may be caused by ovarian cysts, while ectopic pregnancy is associated with amenorrhoea and lower abdominal pain.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Surgical management is recommended for ectopic pregnancies that are larger than 35mm or have a serum B-hCG level greater than 5,000 IU/L. In this case, the patient is experiencing typical symptoms of an ectopic pregnancy, including vaginal bleeding and referred shoulder tip pain. The ultrasound confirms the presence of a tubal ectopic, with a mass exceeding 35mm and tubal ring sign. Therefore, a laparoscopic salpingectomy is the appropriate surgical intervention.
Adrenalectomy is not relevant in this case, as the complex adnexal mass refers to the ectopic pregnancy located near the ovaries, uterus, and fallopian tubes, not the adrenal glands.
Expectant management is not suitable for this patient, as her serum b-hCG is significantly elevated, and the mass exceeds 35mm in size.
Medical management with methotrexate is an option for ectopic pregnancies that are smaller than 35mm or have a serum B-hCG level below 5,000 IU/L.
Ultrasound-guided potassium chloride injection is an alternative to methotrexate for medical management, but it is not currently standard practice in the UK.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

The Levonorgestrel intrauterine system is the appropriate choice for this patient as it is a long-acting contraceptive that can also help prevent heavy menstrual bleeding. It can be inserted immediately as the patient is within 48 hours of childbirth. The Copper intrauterine device should be avoided in those with a history of heavy menstrual bleeding. The lactational amenorrhoea method is only effective for up to 6 months post-partum, and progesterone injections must be repeated every 10-12 weeks, making them unsuitable for this patient’s desire for a long-term contraceptive.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

When a cervical cancer screening smear is inadequate, the recommended course of action is to repeat the smear within 3 months. It is not necessary to consider any previous inadequate smears from a decade ago. Therefore, repeating the smear in 1 month or 3 years is not appropriate. Referral for colposcopy or gynaecology is also not necessary at this stage, as it should only be considered if the second smear in 3 months’ time is also inadequate.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

According to Good Medical Practice (2013), if you have a conscientious objection to a particular procedure, it is your responsibility to inform your patients and explain their right to see another doctor. You must provide them with sufficient information to exercise this right without expressing any disapproval of their lifestyle, choices, or beliefs. It is important to ensure that your personal views do not unfairly discriminate against patients or colleagues and do not affect the treatment you provide or arrange.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

Diagnosis and Testing for Trichomoniasis: A Common STD

Trichomoniasis is a sexually transmitted disease caused by the protozoan parasite T. vaginalis. While both men and women can be affected, women are more likely to experience symptoms. Diagnosis of trichomoniasis is typically made through wet mount microscopy and direct visualisation, with DNA amplification techniques offering higher sensitivity. Urine testing is not considered the gold standard, and cervical swabs are not sensitive enough. Treatment involves a single dose of metronidazole, and sexual partners should be treated simultaneously. Trichomoniasis may increase susceptibility to HIV infection and transmission. Symptoms in women include a yellow-green vaginal discharge with a strong odour, dysuria, pain on intercourse, and vaginal itching. Men may experience penile irritation, mild discharge, dysuria, or pain after ejaculation.

Wheelchair users should not be prescribed the COCP as their immobility increases the risk of developing DVTs, outweighing the benefits of using this form of contraception (UKMEC 3). Past history of depression, family history of ovarian cancer, and smoking history are not significant factors in determining the suitability of COCP use.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Management of Premenstrual Syndrome (PMS)

Premenstrual Syndrome (PMS) is a diagnosis of exclusion, characterized by cyclical psychological, behavioral, and physical symptoms during the luteal phase of the menstrual cycle. The exact causes are not yet identified, but studies suggest that the effects of hormones on serotonin and GABA signaling may have a significant role, in addition to psychological and environmental factors.

For moderate PMS, the National Institute for Health and Care Excellence (NICE) recommends the use of new-generation combined oral contraceptives, which prevent the natural cyclical change in hormones seen in the physiological menstrual cycle. Continuous use, rather than cyclical, showed better improvement. Response is unpredictable, and NICE suggests a trial of three months, and then to review.

Referral to a specialist clinic is reserved for women who have severe PMS, resistant to medication, that cannot be managed in the community. Fluoxetine, a selective serotonin reuptake inhibitor, has been used successfully in the treatment of women with severe PMS symptoms or in women with moderate PMS that fails to respond to other treatments.

Lifestyle modification advice is given to patients with mild PMS, including regular exercise, restriction in alcohol intake, smoking cessation, regular meals, regular sleep, and stress reduction. St John’s wort, an over-the-counter herbal remedy, has shown improvement of symptoms in some studies, but its safety profile is unknown, and it can interact with prescribed medication. Its use is at the discretion of the individual, but the patient needs to be warned of the potential risks.

Management Options for Premenstrual Syndrome (PMS)

Co-cyprindiol is a medication that combines cyproterone acetate and ethinyl estradiol. It is commonly used to treat women with PCOS who have hirsutism and acne. Cyproterone acetate is an anti-androgen that reduces sebum production, leading to a reduction in acne and hirsutism. It also inhibits ovulation and induces regular withdrawal bleeds. However, it should not be used solely for contraception due to its higher risk of venous thromboembolism compared to other conventional contraceptives.

Topical retinoids are a first-line treatment for mild to moderate acne. They can be used alone or in combination with benzoyl peroxide.

Clomiphene citrate is a medication used to induce ovulation in women with PCOS who wish to conceive. It has been associated with increased rates of pregnancy.

Desogestrel is a progesterone-only pill that induces regular bleeds and provides contraception. However, its effect on improving acne and hirsutism is inferior to combination drugs like co-cyprindiol.

Isotretinoin is a medication that regulates epithelial cell growth and is used to treat severe acne resistant to other treatments. It is highly teratogenic and should only be started by an experienced dermatologist in secondary care. Adequate contraceptive cover is necessary, and patients should avoid conception for two years after completing treatment.

Treatment Options for Symptomatic Cystocoele: Lifestyle Modifications, Medications, and Surgeries

Symptomatic cystocoele can be treated through various options, depending on the severity of the condition. The first line of treatment focuses on lifestyle modifications, such as smoking cessation and weight loss. Topical oestrogen may also be prescribed to post- or perimenopausal women suffering from vaginal dryness, urinary incontinence, recurrent urinary tract infections, or superficial dyspareunia. Inserting a ring pessary is the second line of treatment, which needs to be changed every six months and puts the patient at risk of ulceration. Per vaginal surgery is the third line of treatment, which is only possible if the cystocoele is small and puts the patient at risk of fibroids and adhesions. Hysterectomy is not recommended as it increases the risk of cystocoele due to the severance of the uterine ligaments and reduction in support following removal of the uterus.

The most common reason for delayed puberty in women is constitutional delay, which is a normal variation where puberty starts later than usual. This may be due to a family history of late menarche. However, it is important to refer the patient to a specialist for further investigation. Hypogonadotrophic hypogonadism is another cause, which is a result of a deficiency in gonadotrophin-releasing hormone secretion. This can be managed by restoring weight in cases such as athletes, dancers, or anorexia sufferers. Primary gonadal failure is rare and may occur in isolation or as part of chromosomal anomalies. Hormone replacement therapy is the treatment for this condition. Hyperprolactinaemia is a rare cause of primary amenorrhoea, which is caused by high levels of prolactin from a tumour. However, it is unlikely to affect normal development. Hypothyroidism can also cause amenorrhoea, but it is usually accompanied by other symptoms such as cold intolerance, mood changes, and weight gain.

To address the patient’s condition, it is recommended to refer her to the postmenopausal bleeding clinic for an endometrial biopsy. According to the Faculty of Sexual and Reproductive Health, women aged 45 years who use hormonal contraception and experience persistent problematic bleeding or a change in bleeding pattern should undergo endometrial biopsy. Given that the patient is obese and has type two diabetes, both of which are risk factors for endometrial malignancy, watchful waiting and reassurance are not appropriate responses. While the Mirena may be nearing the end of its lifespan after 4 years of insertion, bleeding cannot be attributed to this without ruling out underlying pathology. Hormone replacement therapy is not recommended for this patient at this time.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Understanding Ovarian Stromal Hyperthecosis and Differential Diagnosis

Ovarian stromal hyperthecosis is a condition characterized by the proliferation of ovarian stroma and clusters of luteinizing cells throughout the ovarian stroma. This results in increased secretion of androstenedione and testosterone, leading to hirsutism and virilism. In obese patients, the conversion of androgen to estrogen in peripheral adipose tissue can cause a hyperestrogenic state, which may lead to endometrial hyperplasia and abnormal uterine bleeding. Treatment for premenopausal women is similar to that for polycystic ovary syndrome, while bilateral oophorectomy is preferred for postmenopausal women.

Differential diagnosis for virilization symptoms includes adrenal tumor, Sertoli-Leydig cell tumor, polycystic ovary cyst, and theca lutein cyst. Adrenal tumors may present with additional symptoms such as easy bruising, hypertension, and hypokalemia. Sertoli-Leydig cell tumors are unilateral and more common in women in their second and third decades of life. Polycystic ovary syndrome is limited to premenopausal women, while theca lutein cysts do not cause virilization and can be seen on ultrasound.

Management Options for Menorrhagia Secondary to Fibroids

Menorrhagia secondary to fibroids is a common gynecological problem that can significantly impact a woman’s quality of life. There are several management options available, depending on the severity of symptoms, the patient’s desire for fertility preservation, and the presence of other medical conditions.

Tranexamic acid is the first-line medical management option for women with menorrhagia secondary to fibroids who do not want contraception. It is an antifibrinolytic agent that reduces bleeding by inhibiting the conversion of plasminogen to plasmin. Hormonal therapies, such as combined oral contraceptives, are not indicated in this scenario.

Surgical options, such as myomectomy, endometrial ablation, or hysterectomy, may be considered if medical management fails or the patient declines medication. Myomectomy is a surgical procedure that removes fibroids while preserving the uterus and fertility. However, fibroids can recur following myomectomy. Hysterectomy is the only definitive method of management, but it is only recommended for women who have completed their family.

Iron supplementation with ferrous sulfate is appropriate for patients with iron deficiency anemia secondary to menorrhagia. Mefenamic acid, an NSAID, is contraindicated in patients with inflammatory bowel disease due to the increased risk of gastrointestinal bleeding. The levonorgestrel intrauterine system (Mirena® coil) is recommended as the first-line treatment for menorrhagia without underlying pathology, suspected or diagnosed adenomyosis, or small fibroids that do not cause uterine distortion, but it is not appropriate for women who want to conceive.

In conclusion, the management of menorrhagia secondary to fibroids requires a tailored approach that takes into account the patient’s symptoms, desire for fertility preservation, and medical history. A multidisciplinary team approach involving gynecologists, hematologists, and other specialists may be necessary to provide optimal care.

Common Causes of Lumps in the Vaginal Area in Women

The vaginal area in women can be affected by various lumps, which can cause discomfort and concern. Here are some of the most common causes of lumps in the vaginal area in women:

Bartholin Cyst: This type of cyst occurs when the ducts connecting the Bartholin glands, which are located near the introitus at the 4 and 8 o’clock positions, become obstructed. Bartholin cysts are usually soft, small, and asymptomatic, but they can cause discomfort and require removal in women over 40 to rule out vaginal carcinoma.

Lipoma: A lipoma is a benign adipose tissue that can be found on the labia majora. It is a larger and rarer lump than a Bartholin cyst.

Bartholin Abscess: This condition arises from an infected Bartholin cyst and causes significant labial swelling, erythema, tenderness, and pain on micturition and superficial dyspareunia. Treatment includes antibiotics and warm baths, but surgical management may be necessary.

Haematoma: A haematoma is a collection of blood cells outside the vessels, which presents as a firm, red-purple lump. It usually occurs after trauma or surgery.

Infected Epidermal Cyst: Epidermal cysts are benign tumors that can occur in the perineal area. When infected, they cause erythema, pain, and extravasation of keratin material.

Understanding the Different Types of Lumps in the Vaginal Area in Women

Women can begin using hormonal contraception right away after taking levonorgestrel (Levonelle) for emergency contraception. However, if ulipristal acetate was used instead, it is recommended to wait for 5 days or use barrier methods before resuming hormonal contraception.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Differential Diagnosis for Severe Iliac Fossa Pain in Reproductive-Age Women

Severe, sudden-onset pain in the right or left iliac fossa is a common symptom of ectopic pregnancy in reproductive-age women. This pain may be accompanied by vaginal bleeding, shoulder tip pain, syncopal episodes, and shock. To rule out pregnancy, a urinary beta human chorionic gonadotrophin hormone (b-HCG) test should be performed, followed by a transvaginal ultrasound scan to confirm the diagnosis.

Ovarian torsion may also cause iliac fossa pain, but it is unlikely to cause referred shoulder pain. Appendicitis is not a consideration in this scenario, as the patient does not have an appendix. Irritable bowel syndrome and inflammatory bowel disease are also unlikely diagnoses, as the patient’s tachycardia and right iliac fossa tenderness and guarding are not consistent with these conditions. Overall, a thorough evaluation is necessary to differentiate between these potential causes of severe iliac fossa pain in reproductive-age women.

The most frequent location for ectopic pregnancy is the ampulla of the fallopian tube. While other sites are also feasible, the ampulla is the most prevalent, making it the most suitable response.

Understanding Ectopic Pregnancy: The Pathophysiology

Ectopic pregnancy is a medical condition where the fertilized egg implants outside the uterus, usually in the fallopian tube. According to statistics, 97% of ectopic pregnancies occur in the fallopian tube, with most of them happening in the ampulla. However, if the implantation occurs in the isthmus, it can be more dangerous. The remaining 3% of ectopic pregnancies can occur in the ovary, cervix, or peritoneum.

During ectopic pregnancy, the trophoblast, which is the outer layer of the fertilized egg, invades the tubal wall, leading to bleeding that may dislodge the embryo. The natural history of ectopic pregnancy involves three possible outcomes: absorption, tubal abortion, or tubal rupture.

Tubal abortion occurs when the embryo dies, and the body expels it along with the blood. On the other hand, tubal absorption occurs when the tube does not rupture, and the blood and embryo are either shed or converted into a tubal mole and absorbed. However, if the tube ruptures, it can lead to severe bleeding, shock, and even death.

In conclusion, understanding the pathophysiology of ectopic pregnancy is crucial in diagnosing and managing this potentially life-threatening condition. Early detection and prompt treatment can help prevent complications and improve outcomes.

Atrophic vaginitis is a condition that commonly affects women who have gone through menopause. Its symptoms include vaginal dryness, pain during sexual intercourse, and occasional spotting. Upon examination, the vagina may appear dry and pale. The recommended treatment for this condition is the use of vaginal lubricants and moisturizers. If these do not provide relief, a topical estrogen cream may be prescribed.

Patients with secondary dysmenorrhoea require referral to gynaecology for further investigation. This is because secondary dysmenorrhoea, which is characterized by painful cramping in the lower abdomen before or after menstruation along with new menorrhagia, suggests an underlying pathology that needs to be addressed. While mefenamic acid can help manage the pain, it is not enough to simply review the patient in two weeks without organizing referrals or investigations. The insertion of an intrauterine progesterone system may be appropriate for primary dysmenorrhoea and some cases of secondary dysmenorrhoea, but this should not be the only course of action. Additional analgesia should be considered if paracetamol is not controlling the pain. An abdominal ultrasound is not suitable for investigating pelvic organs, and a transabdominal or transvaginal pelvic ultrasound is necessary to obtain views of the uterus, ovaries, Fallopian tubes, cervix, and vagina.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

Disorders of Sexual Development: An Overview

Disorders of sexual development (DSD) are a group of conditions that affect the development of the reproductive system. Here are some of the most common DSDs:

Androgen Insensitivity Syndrome (AIS)
AIS is a condition where cells cannot respond to androgens, resulting in disrupted sexual development. Patients with complete AIS have a female phenotype with male internal genitalia, while those with partial or mild AIS may have a mix of male and female characteristics. Treatment involves careful gender assignment and hormone replacement therapy.

Turner Syndrome
Turner syndrome is a condition where patients are missing all or part of an X chromosome, resulting in premature ovarian failure and delayed puberty. Patients are phenotypically female with normal external genitalia.

Klinefelter’s Syndrome
Klinefelter’s syndrome is a chromosomal aneuploidy where patients have an extra copy of an X chromosome, resulting in hypogonadism and infertility. Patients are phenotypically male with normal external genitalia.

Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia is a group of conditions associated with abnormal enzymes involved in the production of hormones from the adrenals. Patients may have ambiguous genitalia at birth and later present with symptoms of polycystic ovary syndrome or hyperpigmentation.

5-α Reductase Deficiency
5-α reductase deficiency is a condition where patients have a mutation in the SDR5A2 gene, resulting in disrupted formation of external genitalia before birth. Patients may have ambiguous genitalia at birth and later show virilisation during puberty. Patients are infertile.

Treatment for DSDs involves hormone replacement therapy and supportive care. It is important to provide psychosocial support for patients and their families.

Menopausal patients typically exhibit a significant increase in their levels of follicle stimulating hormone (FSH). Therefore, testing for FSH can be used to confirm menopause. FSH, along with luteinising hormone (LH), are gonadotropins that are released by the anterior pituitary gland into the bloodstream. These hormones stimulate the growth and maturation of the follicle in the ovaries. The levels of FSH and LH in circulation are regulated by negative feedback to the hypothalamus, which is influenced by steroid hormones produced by the ovaries. However, when ovarian function ceases, as in menopause or premature ovarian failure, the negative feedback mechanisms are removed, leading to high levels of FSH.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flashes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Types of Vulval Cancer: Symptoms, Diagnosis, and Treatment

Vulval cancer is a rare type of cancer that affects the external female genitalia. There are different types of vulval cancer, each with its own set of symptoms, risk factors, and treatment options. Here are some of the most common types of vulval cancer:

Squamous cell carcinoma: This is the most common type of vulval cancer, accounting for about 85% of cases. It usually affects women over 60 who smoke or have a weakened immune system. Symptoms include vulval irritation or itching, and as the disease progresses, pain and discharge. Squamous cell carcinoma can be cured if caught early, and treatment usually involves surgical excision.

Basal cell carcinoma: This type of vulval cancer is rare and usually occurs in sun-exposed areas of the skin. It is often treated with surgery.

Sarcoma: Sarcoma is a rare type of vulval cancer that can occur at any age, including childhood. Treatment usually involves surgery and radiation therapy.

Bartholin’s gland carcinoma: This is a rare cause of vulval cancer that affects the Bartholin glands, which are two small mucous-producing glands on either side of the vaginal opening. Risk factors include HPV infection and Paget’s disease of the vulva. It is often diagnosed late, as it is often confused with Bartholin gland cyst, which is a benign condition.

Malignant melanoma: This is a rare type of vulval cancer that accounts for about 5% of cases. Symptoms include itching, bleeding, and an irregular border. Treatment usually involves surgery and chemotherapy.

If you experience any symptoms of vulval cancer, such as itching, pain, or bleeding, it is important to see a doctor as soon as possible. Early diagnosis and treatment can improve your chances of a full recovery.

On ultrasound imaging, the presence of a whirlpool sign and free fluid may indicate ovarian torsion. This sign occurs when a structure twists upon itself. It is important to note that appendicitis and ectopic pregnancy do not show this sign on imaging. Additionally, the pain associated with Mittelschmerz is typically less severe and would not be accompanied by the ultrasound finding.

Understanding Ovarian Torsion

Ovarian torsion is a medical condition that occurs when the ovary twists on its supporting ligaments, leading to a compromised blood supply. This condition can be partial or complete and may also affect the fallopian tube, which is then referred to as adnexal torsion. Women who have an ovarian mass, are of reproductive age, pregnant, or have ovarian hyperstimulation syndrome are at a higher risk of developing ovarian torsion.

The most common symptom of ovarian torsion is sudden, severe abdominal pain that is colicky in nature. Patients may also experience vomiting, distress, and in some cases, fever. Upon examination, adnexal tenderness may be detected, and an ultrasound may show free fluid or a whirlpool sign. Laparoscopy is usually both diagnostic and therapeutic for this condition.

Ectopic Pregnancy: A Gynaecological Emergency

Ectopic pregnancy is a serious condition that requires immediate medical attention. It occurs when a fertilized egg implants outside the uterus, usually in the fallopian tube. This can lead to life-threatening complications if left untreated. Risk factors for ectopic pregnancy include a history of pelvic inflammatory disease (PID), previous terminations, and a positive pregnancy test.

A woman’s ovulation usually occurs on day 14 of her 28-day menstrual cycle. After ovulation, hormonal changes occur.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

The appropriate answer is that the woman cannot use the pill anymore due to an unacceptably high clinical risk. She has developed systemic lupus erythematosus (SLE) with positive antiphospholipid antibodies, which is classified as UK Medical Eligibility Criteria for Contraceptive Use UKMEC 4, meaning it is an absolute contraindication. The risks of arterial and venous thrombosis would be too high if she were to restart the combined pill, and alternative contraceptive options should be considered. It is important to note that both SLE with positive antiphospholipid antibodies and isolated presence of antiphospholipid antibodies are classified as UKMEC 4 conditions, but not the diagnosis of antiphospholipid syndrome. The advantages of using the pill generally outweigh the risks is an incorrect answer, as it is equivalent to UKMEC 2. The correct answer would be applicable if the woman did not test positive for any of the three antiphospholipid antibodies or if she did not test positive again after 12 weeks. The risks usually outweigh the advantages of using the combined pill is also incorrect, as it is equivalent to UKMEC 3. Lastly, there is no risk or contraindication to her restarting the combined pill is an incorrect answer, as it is equivalent to UKMEC 1.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Investigating Infertility: Recommended Tests and Procedures

When a patient presents with infertility, there are several tests and procedures that can be performed to identify the underlying cause. In the case of a patient with known co-morbidities such as previous ectopic pregnancy, pelvic inflammatory disease, or endometriosis, laparoscopy and dye is the most appropriate next step of investigation. This procedure involves Exploratory laparoscopy, allowing direct visualisation of the pelvis, and injection of dye into the uterus to assess tubal patency.

Luteinising hormone (LH) and follicle-stimulating hormone (FSH) testing is typically performed when a patient has irregular menses, but may not be necessary for those with regular cycles and normal mid-luteal progesterone levels indicating ovulation. Basal body temperature charts are not recommended by NICE guidelines, as a mid-luteal phase progesterone blood test is a more accurate measure of ovulation.

Cervical smears may be indicated if the patient is due for screening, but do not form part of infertility investigations. Hysterosalpingography is recommended by NICE guidelines for women without co-morbidities, but is not appropriate for those with a history of endometriosis. Understanding the appropriate tests and procedures for investigating infertility can help healthcare providers identify the underlying cause and develop an effective treatment plan.

According to NICE guidelines for cervical screening, if the smear test is inadequate or the high-risk human papillomavirus (hrHPV) test result is unavailable, the sample should be repeated within 3 months. Therefore, repeating the sample in 3 months is the correct course of action. Repeating HPV testing in 1 week would not change the management plan as Sarah has already tested positive for hrHPV and requires an adequate cervical cytology result. Colposcopy is only necessary if there are two consecutive inadequate results. Waiting 12 months to repeat the sample would be inappropriate as it would be too long between tests. Similarly, returning Sarah to routine recall is not appropriate as she requires an adequate cytology result.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Teratomas, also known as dermoid cysts, are non-cancerous tumors that originate from multiple germ cell layers. These tumors can produce a variety of tissues, including skin, hair, blood, fat, bone, nails, teeth, cartilage, and thyroid tissue, due to their germ cell origin.

Mature cystic teratomas have a white shiny mass or masses projecting from the wall towards the center of the cyst. This protuberance is called the Rokitansky protuberance and is where hair, bone, teeth, and other dermal appendages usually arise from.

While ovarian malignancy is rare in young females, suspicion can be assessed using the risk of malignancy index (RMI), which takes into account serum CA-125 levels, ultrasound findings, and menopausal status.

Understanding the Different Types of Ovarian Cysts

Ovarian cysts are a common occurrence in women, and they can be classified into different types. The most common type of ovarian cyst is the physiological cyst, which includes follicular cysts and corpus luteum cysts. Follicular cysts occur when the dominant follicle fails to rupture or when a non-dominant follicle fails to undergo atresia. These cysts usually regress after a few menstrual cycles. Corpus luteum cysts, on the other hand, occur when the corpus luteum fails to break down and disappear after the menstrual cycle. These cysts may fill with blood or fluid and are more likely to cause intraperitoneal bleeding than follicular cysts.

Another type of ovarian cyst is the benign germ cell tumour, which includes dermoid cysts. Dermoid cysts are also known as mature cystic teratomas and are usually lined with epithelial tissue. They may contain skin appendages, hair, and teeth. Dermoid cysts are the most common benign ovarian tumour in women under the age of 30, and they are usually asymptomatic. However, torsion is more likely to occur with dermoid cysts than with other ovarian tumours.

Lastly, there are benign epithelial tumours, which arise from the ovarian surface epithelium. The most common benign epithelial tumour is the serous cystadenoma, which bears a resemblance to the most common type of ovarian cancer (serous carcinoma). Serous cystadenomas are bilateral in around 20% of cases. The second most common benign epithelial tumour is the mucinous cystadenoma, which is typically large and may become massive. If it ruptures, it may cause pseudomyxoma peritonei.

In conclusion, understanding the different types of ovarian cysts is important for proper diagnosis and treatment. Complex ovarian cysts should be biopsied to exclude malignancy, while benign cysts may require monitoring or surgical removal depending on their size and symptoms.

Treatment Options for Menopausal Symptoms in Breast Cancer Patients

Breast cancer patients experiencing mood disturbance, anxiety, and depression related to menopausal symptoms can benefit from cognitive behavioural therapy (CBT) and lifestyle modifications. A 2-week trial of fluoxetine may be an option, but it is contraindicated in patients receiving tamoxifen therapy. Combined cyclic hormonal replacement therapy (HRT) is not routinely offered due to the increased risk of breast cancer recurrence, but can be prescribed in exceptional circumstances. Over-the-counter herbal products like black cohosh are not recommended due to safety concerns and potential interactions with medications. Lifestyle changes such as reducing caffeine and alcohol consumption, using a handheld fan, and regular exercise can also help alleviate symptoms.

The most reliable way to confirm ovulation is through the Day 21 progesterone test. This test measures the peak level of progesterone in the serum, which occurs 7 days after ovulation. While the length of the follicular phase can vary, the luteal phase always lasts for 14 days. Therefore, if a woman has a 35-day cycle, she can expect to ovulate on Day 21 and her progesterone level will peak on Day 28. To determine when to take the test, subtract 7 days from the expected start of the next period (Day 21 for a 28-day cycle and Day 28 for a 35-day cycle). Basal body temperature charts and cervical mucous thickness are not reliable predictors of ovulation. Gonadotropins may be used to assess ovarian function in women with irregular menstrual cycles.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

Diagnostic Modalities for Endometriosis: Exploratory Laparoscopy, Transabdominal Ultrasound, Hysterosalpingography, MRI Abdomen Pelvis, and CA-125

Endometriosis is a condition where endometrial tissue grows outside the endometrial cavity, causing cyclical proliferation and bleeding. It can lead to scarring, adhesions, and cysts with haemorrhagic contents. The classic symptoms are dyspareunia, infertility, cyclical pelvic pain, and dysmenorrhoea. Diagnosis is often made through Exploratory laparoscopy, where small, dark purple-black spots on the peritoneum can be identified and sampled for histological analysis. Transabdominal ultrasound is not very sensitive at detecting small deposits, but can detect endometriotic cysts. Hysterosalpingography is recommended for investigating infertility and recurrent miscarriage, but is not a definitive diagnosis for endometriosis. MRI of the pelvis is sensitive for endometriomas and adnexal masses, but not small deposits. CA-125 testing is not recommended for diagnosis.

Understanding Hormone Replacement Therapy (HRT) for perimenopausal Symptoms

perimenopausal symptoms can significantly affect a woman’s daily routine, work, and mood. Hormone Replacement Therapy (HRT) is one of the treatment options available for managing these symptoms. However, before commencing HRT, patients need to be consulted and informed of the risks and benefits associated with this treatment.

HRT can be either oestrogen replacement only or combined. Combined HRT is given to women who have a uterus, as oestrogen alone can increase the risk of developing endometrial cancer. Combined HRT can be either cyclical or continuous, depending on the patient’s menopausal status.

For women with irregular menses, a cyclical regime is indicated. This involves taking an oestrogen tablet once daily for a 3-month period, with norethisterone added on the last 14 days. Patients on this regime have a period every three months. Once a woman has completed a year on cyclical therapy or has established menopause, then she can change to combined continuous HRT.

It is important to note that oestrogen-only HRT is only given to women who have had a hysterectomy. Oestrogen therapy alone increases the risk of developing endometrial hyperplasia and endometrial carcinoma. Therefore, in women who have a uterus, combined HRT, with the addition of a progesterone, is preferred to reduce this risk.

In summary, HRT is a treatment option for perimenopausal symptoms. The type of HRT prescribed depends on the patient’s menopausal status and whether they have a uterus. Patients need to be informed of the risks and benefits associated with HRT before commencing treatment.

Surgical intervention is necessary for the management of ectopic pregnancy.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

The GMC has issued new guidance stating that all instances of female genital mutilation (FGM) must be reported to the police if the victim is under 18 years old. Failure to do so could result in a breach of GMC guidelines and put a doctor’s registration at risk. However, this mandatory duty does not apply to victims over 18 years old, or if another doctor has already reported the same act of FGM to the police. It is not recommended to involve the patient’s family in discussions about FGM, as this may cause further distress. Instead, doctors should focus on making a police report and may also need to contact child protection services. Referring the patient to secondary care for treatment of FGM symptoms may be helpful, but a police report must still be made.

Understanding Female Genital Mutilation

Female genital mutilation (FGM) is a term used to describe any procedure that involves the partial or complete removal of the external female genitalia or any other injury to the female genital organs for non-medical reasons. The World Health Organization (WHO) has classified FGM into four types. Type 1 involves the partial or total removal of the clitoris and/or the prepuce, while type 2 involves the partial or total removal of the clitoris and the labia minora, with or without excision of the labia majora. Type 3 involves the narrowing of the vaginal orifice with the creation of a covering seal by cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris. Finally, type 4 includes all other harmful procedures to the female genitalia for non-medical purposes, such as pricking, piercing, incising, scraping, and cauterization. It is important to understand the different types of FGM to raise awareness and prevent this harmful practice.

A rupture endometrioma can result in a sudden and severe pain, given the patient’s medical history of endometriosis, acute abdomen, and fluid accumulation in the pelvis. Diverticular disease is an improbable diagnosis in this age group and does not match the symptoms described. Additionally, the patient’s current menstrual cycle rules out endometriosis pain as a possible cause.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

First-Line Treatment for Couples Trying to Conceive

When a couple is trying to conceive, lifestyle measures should be the first-line treatment. This includes weight loss and quitting smoking, as both can negatively impact fertility. It’s also important to check for folic acid intake, alcohol and drug use, previous infections, and mental health issues. If the couple is having regular sexual intercourse without contraception, 84% will become pregnant within a year and 92% within two years. Therefore, further investigations and referrals to infertility services are not recommended until after a year of trying. Blood tests are not necessary if the woman is having regular periods. Sperm analysis can be performed after a year of trying, and a female pelvic ultrasound is not necessary at this point. The focus should be on lifestyle changes to improve the chances of conception.

Premenstrual syndrome (PMS) can be helped by SSRIs, either continuously or during the luteal phase. If a patient’s symptoms are significantly impacting their day-to-day life and have not improved with first-line treatment using a combined oral contraceptive pill, antidepressant treatment with SSRIs is recommended. Co-cyprindiol, levonorgestrel-releasing intrauterine systems, mirtazapine, and the copper coil are not indicated for the management of PMS.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

A high vaginal swab is not necessary for diagnosing vaginal candidiasis if the symptoms strongly suggest its presence. Symptoms such as genital itching and white discharge are indicative of Candida albicans infection. The discharge appears like cottage cheese and causes inflammation and itching, but the vaginal pH remains normal (around 4.0-4.5 in women of reproductive age). Since vaginal candidiasis is a common condition, a confident clinical suspicion based on the examination can be enough to diagnose and initiate treatment.

The other options for diagnosis are incorrect. Gardnerella vaginalis is a normal part of the vaginal flora, but it’s overgrowth can lead to bacterial vaginosis. Unlike vaginal candidiasis, bacterial vaginosis presents with thinner white discharge and a fishy odor that intensifies with the addition of potassium hydroxide. Additionally, the vaginal pH would be elevated (> 4.5).

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

The combined oral contraceptive pill (COCP) is a highly effective birth control method that contains both oestrogen and progesterone. Studies have shown that the use of COCP can increase or decrease the risk of certain cancers. It has been found that the use of COCP can decrease the risk of endometrial cancer by suppressing the growth of endometrial cells. However, prolonged use of COCP has been associated with an increased risk of breast cancer, as synthetic hormones in the pill may stimulate the growth of breast cancer cells. Similarly, the use of COCP has been linked to an increased risk of cervical cancer, as it may make cervical cells more susceptible to human papillomavirus infections. It is important to note that COCP does not provide protection against sexually transmitted infections. Additionally, the use of oestrogen-containing contraception has been associated with an increased risk of strokes and ischaemic heart disease, particularly in patients with additional risk factors such as smoking and diabetes. The exact mechanism for this increased risk is not yet clear, but it may be due to increased blood pressure and/or hypercoagulation.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than 1 per 100 woman years. It does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to the combined oral contraceptive pill. One of the main issues is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side-effects such as headache, nausea, and breast tenderness may also be experienced.

It is important to weigh the pros and cons of the combined oral contraceptive pill before deciding if it is the right method of birth control for you. While some users report weight gain while taking the pill, a Cochrane review did not support a causal relationship. Overall, the combined oral contraceptive pill can be an effective and convenient method of birth control, but it is important to discuss any concerns or potential risks with a healthcare provider.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

If a woman of reproductive age has been having unprotected vaginal sexual intercourse for a year without conceiving and there is no known cause of infertility, NICE guidance recommends that she and her partner undergo further clinical assessment and investigation. The most appropriate initial investigation for this patient is a day 21 progesterone test, which is non-invasive and can determine if the patient is ovulating. Serum prolactin and thyroid function tests are not recommended unless there is a specific reason for testing, such as a pituitary tumor or overt thyroid disease. Transvaginal or abdominal ultrasounds are unlikely to reveal the cause of subfertility and are therefore not necessary. As part of the initial assessment, the male partner should also undergo a semen analysis.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

There are many options available for contraception, each with their own advantages and disadvantages. It is important to discuss these options to find the best fit for the patient. In this case, the progesterone only contraceptive pill is the most appropriate option due to the patient’s history of migraine with aura and heavy menstrual cycle. The combined oral contraceptive pill is not recommended for this patient. The intrauterine system is a popular option for menorrhagia, but the patient does not want an invasive device. The contraceptive implant is also invasive and not preferred by the patient. Condoms are a good barrier method, but the POCP will also help with the patient’s heavy and irregular periods.

Management of Vaginal Atrophy in Menopausal Women

Menopausal women often experience vaginal atrophy due to oestrogen deficiency, leading to a variety of symptoms such as dyspareunia, burning, irritation, vaginal discharge, and bleeding. It is crucial to rule out urinary and sexually transmitted infections and perform a speculum examination to exclude malignancy in the presence of vaginal bleeding. Topical therapy is the first-line management for vaginal atrophy, which can be either hormonal or non-hormonal. Hormonal treatments are more effective but have more side-effects, while non-hormonal treatments provide symptom relief to a number of patients. A combination of both therapies is also an option for maximal symptom relief. Systemic hormonal replacement therapy is offered to women who have both vaginal and systemic menopausal symptoms. Vaginal bleeding is a common side-effect of hormonal treatment and requires further investigation if it persists after the first six months of therapy.

After undergoing treatment for cervical intraepithelial neoplasia (CIN) during her colposcopy appointment, this woman needs to undergo follow-up cervical screening to ensure that the lesion has been effectively treated. Women who have received treatment for CIN II should be provided with cervical screening and an HPV test of cure after 6 months. If the test results are positive, the woman should go back for colposcopy.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Premenstrual Dysphoric Disorder: Symptoms, Diagnosis, and Differential Diagnosis

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) characterized by psychological and behavioral symptoms in the absence of physical symptoms. PMS is a condition that affects the majority of women in reproductive age, with symptoms occurring in the luteal phase of the menstrual cycle and resolving with menstruation. The exact causes of PMS and PMDD are not yet identified, but hormonal effects on neurotransmitters and psychological and environmental factors may play a role.

To diagnose PMS or PMDD, organic causes must be excluded through a full history, examination, and blood tests. A prospective diary of symptoms over 2-3 menstrual cycles can also aid in diagnosis. Symptoms must be present in the luteal phase and improve or resolve with menstruation.

Differential diagnosis for PMDD includes depression, hypothyroidism, and hyperthyroidism. Depression symptoms are continuous and not subject to regular cycling, while hypothyroidism symptoms are persistent and not cyclical. Hyperthyroidism may present with symptoms mimicking mania and psychosis.

Mild PMS does not interfere with daily activities or social and professional life, while moderate and severe PMS can impact a woman’s ability to carry out activities. PMDD is a severe form of PMS characterized by psychological and behavioral symptoms in the absence of physical symptoms.

Diagnosis of Androgen Insensitivity Syndrome: A Case Study

The presented case strongly suggests the presence of androgen insensitivity syndrome, a condition where a patient’s phenotype and secondary sexual characteristics differ from their karyotype and gonads. In this case, the patient is likely to have a karyotype of 46,XY and be a male pseudohermaphrodite. Androgen insensitivity syndrome is associated with mutations in the AR gene, which codes for the androgen receptor. In complete androgen insensitivity, the body cannot respond to androgens at all, resulting in a female phenotype, female secondary sexual characteristics, no uterus, and undescended testes.

Karyotyping is the key diagnostic investigation to confirm the diagnosis of androgen insensitivity syndrome. Serum oestradiol levels may vary according to the type of androgen insensitivity disorder and are unlikely to aid the diagnosis. Pituitary MRI may be a second diagnostic investigation if karyotype abnormalities are ruled out. Transvaginal ultrasound is not necessary if an abdominal ultrasound has already been performed and showed an absent uterus.

Appropriate Treatment Options for Vaginal Infections

Bacterial vaginosis is a common vaginal infection that results in a decrease in lactobacilli and an increase in anaerobic bacteria. The typical symptoms include a white, milky, non-viscous discharge with a fishy odor and a pH greater than 4.5. The recommended treatment for bacterial vaginosis is metronidazole 400 mg twice a day for a week.

Azithromycin is the treatment of choice for Chlamydia, but it is not appropriate for bacterial vaginosis. acyclovir is used to treat herpes infections, which is not the cause of this patient’s symptoms. Fluconazole is a treatment option for vaginal candidiasis, but it is unlikely to be the cause of this patient’s symptoms. Pivmecillinam is used to treat urinary tract infections, which is not the cause of this patient’s symptoms.

In conclusion, the appropriate treatment for bacterial vaginosis is metronidazole, and other treatments should be considered based on the specific diagnosis.

Treatment Options for Sexually Transmitted Infections

Sexually transmitted infections (STIs) can cause a range of symptoms in women, including post-coital bleeding, vaginal discharge, cervicitis, and more. Here are some common treatment options for STIs:

– Metronidazole: This medication is used to treat Trichomonas vaginalis infections. Patients typically take 400-500 mg twice daily for 5-7 days. It’s important to treat the partner simultaneously and abstain from sex for at least one week.
– Referral for colposcopy: If symptoms persist after treatment, patients may be referred for colposcopy to rule out cervical carcinoma.
– Azithromycin or doxycycline: These medications are used to treat uncomplicated genital Chlamydia infections. Most women with a chlamydial infection remain asymptomatic.
– Ceftriaxone and azithromycin: This combination is the treatment of choice for gonorrhoea infections. Symptoms may include increased vaginal discharge, lower abdominal pain, dyspareunia, and dysuria.
– No treatment is required: This is not an option for symptomatic patients with T vaginalis, as it is a sexually transmitted infection that requires treatment.

It’s important to seek medical attention if you suspect you have an STI, as early treatment can prevent complications and transmission to others.

If there is suspicion of ovarian cancer and an abdominal or pelvic mass is present, it is not necessary to perform a CA125 and US test. Instead, the patient should be immediately referred to gynaecology. Prescribing loperamide and buscopan for symptoms of irritable bowel syndrome in women over 50 years old is not appropriate as these symptoms could indicate ovarian cancer and require investigation. While waiting for the results of CA125 and ultrasound tests is usually recommended for suspected ovarian cancer patients, urgent referral to gynaecology is necessary in this case due to the presence of an abdominal mass. Although CA125 measurement should still be performed, waiting for test results to determine the need for urgent referral is not appropriate as guidelines already recommend it.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

Treatment Options for Stress Urinary Incontinence

Stress urinary incontinence is a common condition in women, especially those who have had vaginal deliveries and are getting older. It is caused by weak sphincter muscles, leading to leakage during activities such as coughing, sneezing, laughing, or exercising. The first-line treatment for this condition is pelvic floor muscle training, which involves a minimum of eight contractions three times per day for 12 weeks.

However, it is important to note that other treatment options, such as oxybutynin, pelvic ultrasound scans, urodynamic studies, and bladder training, are not recommended for stress urinary incontinence. Oxybutynin is used for overactive bladder or mixed urinary incontinence, while pelvic ultrasound scans are not indicated for urinary incontinence. Urodynamic studies are not recommended for women with simple stress incontinence on history and examination, and bladder training is used for urgency or mixed urinary incontinence, not stress incontinence. Therefore, pelvic floor muscle training remains the most effective treatment option for stress urinary incontinence.

Ultrasound imaging may reveal a whirlpool sign in cases of ovarian torsion, which is strongly indicated by the patient’s history and examination. The beads-on-a-string sign is typically associated with chronic salpingitis, while hypoechoic masses are often indicative of fibroids. A snow-storm appearance is a characteristic finding in complete hydatidiform mole.

Understanding Ovarian Torsion

Ovarian torsion is a medical condition that occurs when the ovary twists on its supporting ligaments, leading to a compromised blood supply. This condition can be partial or complete and may also affect the fallopian tube, which is then referred to as adnexal torsion. Women who have an ovarian mass, are of reproductive age, pregnant, or have ovarian hyperstimulation syndrome are at a higher risk of developing ovarian torsion.

The most common symptom of ovarian torsion is sudden, severe abdominal pain that is colicky in nature. Patients may also experience vomiting, distress, and in some cases, fever. Upon examination, adnexal tenderness may be detected, and an ultrasound may show free fluid or a whirlpool sign. Laparoscopy is usually both diagnostic and therapeutic for this condition.

If the result of the first repeat smear for cervical cancer screening at 12 months is negative for high-risk human papillomavirus (hrHPV), the patient can resume routine recall. This means they should undergo screening every 3 years from age 25-49 years or every 5 years from age 50-64 years. However, if the repeat test is positive again, the patient should undergo another HPV test in 12 months. If there is dyskaryosis on a cytology sample, the patient should be referred for colposcopy.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The Evra patch is the only contraceptive patch that is approved for use in the UK. The patch cycle lasts for four weeks, during which the patch is worn every day for the first three weeks and changed weekly. During the fourth week, the patch is not worn, and a withdrawal bleed occurs.

If a woman delays changing the patch at the end of week one or two, she should change it immediately. If the delay is less than 48 hours, no further precautions are necessary. However, if the delay is more than 48 hours, she should change the patch immediately and use a barrier method of contraception for the next seven days. If she has had unprotected sex during this extended patch-free interval or in the last five days, emergency contraception should be considered.

If the patch removal is delayed at the end of week three, the woman should remove the patch as soon as possible and apply a new patch on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed.

If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for seven days following any delay at the start of a new patch cycle. For more information, please refer to the NICE Clinical Knowledge Summary on combined hormonal methods of contraception.

Urodynamic studies are necessary when there is a lack of clarity in diagnosis or when surgery is being considered.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

When considering amenorrhoea, it is important to look at the underlying causes. There are two types: primary and secondary. Primary amenorrhoea occurs when a woman has never had a period, while secondary amenorrhoea occurs when a woman who has previously had periods now hasn’t for at least 6 months (or 12 months if she previously had irregular periods).

In cases of primary amenorrhoea, it is important to consider whether the woman has developed normal secondary sexual characteristics. If she has, then a mechanical obstruction may be the cause rather than a hormonal one. It is unusual for a 17-year-old girl with normal secondary sexual characteristics to have never had a period, so waiting a year before reassessment is not appropriate. Clinical judgement should be used, especially with younger women.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

The appropriate medical management for a miscarriage involves administering vaginal misoprostol alone. This is a prostaglandin analogue that stimulates uterine contractions, expediting the passing of the products of conception. Oral methotrexate and oral mifepristone alone are not suitable for managing a miscarriage, as they are used for ectopic pregnancies and terminations of pregnancy, respectively. The combination of oral misoprostol and oral mifepristone, as well as vaginal misoprostol and oral mifepristone, are also not recommended due to limited evidence of their efficacy. The current recommended approach is to use vaginal misoprostol alone, as it limits side effects and has a strong evidence base.

Management Options for Miscarriage

Miscarriage can be a difficult and emotional experience for women. In the 2019 NICE guidelines, three types of management for miscarriage were discussed: expectant, medical, and surgical. Expectant management involves waiting for a spontaneous miscarriage and is considered the first-line option. However, if it is unsuccessful, medical or surgical management may be offered.

Medical management involves using tablets to expedite the miscarriage. Vaginal misoprostol, a prostaglandin analogue, is used to cause strong myometrial contractions leading to the expulsion of tissue. It is important to advise patients to contact their doctor if bleeding does not start within 24 hours. Antiemetics and pain relief should also be given.

Surgical management involves undergoing a surgical procedure under local or general anaesthetic. The two main options are vacuum aspiration (suction curettage) or surgical management in theatre. Vacuum aspiration is done under local anaesthetic as an outpatient, while surgical management is done in theatre under general anaesthetic. This was previously referred to as ‘Evacuation of retained products of conception’.

It is important to note that some situations are better managed with medical or surgical management, such as an increased risk of haemorrhage, being in the late first trimester, having coagulopathies or being unable to have a blood transfusion, previous adverse and/or traumatic experience associated with pregnancy, evidence of infection, and more. Ultimately, the management option chosen should be based on the individual patient’s needs and preferences.

The patient has primary amenorrhoea due to a macroprolactinoma, which is a benign prolactin-secreting tumor of the anterior pituitary gland. Treatment in the first instance is with a dopamine receptor agonist such as bromocriptine or cabergoline. Surgery is the most appropriate management if conservative management fails or the patient presents with visual field defects. Radiotherapy is rarely used. Exclusion of pregnancy is the first step in every case of amenorrhoea. Metoclopramide is a dopamine receptor antagonist and a cause of hyperprolactinaemia, so it should not be used to treat this patient. Thyroxine is not appropriate as hyperprolactinaemia is secondary to a pituitary adenoma. Indications for surgery are failure to respond to medical therapy or presentation with acute visual field defects.

The menopause is a natural process that occurs when a woman’s menstrual periods stop due to decreased production of oestradiol and progesterone. While menopause can cause symptoms such as hot flashes, mood changes, and reduced libido, treatment with hormone replacement therapy (HRT) is not necessary and should be based on individual circumstances and patient choice. However, if HRT is used, it is important to note that oestrogen-only therapy can increase the risk of endometrial cancer and should only be given to women without a uterus. This is because oestrogen promotes endometrial growth, which can lead to oncogenesis. Adding progesterone to HRT can prevent this risk. Testosterone may also be used to address libido issues, but it should be prescribed under specialist guidance and can cause virilising side-effects. Selective serotonin reuptake inhibitors (SSRIs) such as venlafaxine can be an alternative to HRT and are effective at managing symptoms without increasing the risk of endometrial cancer. However, SSRIs can cause side-effects such as gastrointestinal disturbances, reduced libido, and potentially life-threatening serotonin syndrome.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Emergency contraception is necessary if unprotected sex occurred within 48 hours of restarting the POP after a missed pill. In this case, the patient missed her second pill by over 12 hours and is within the 48-hour window. A pregnancy test cannot provide reassurance the day after intercourse. It is important to take additional precautions and take the next pill at the normal time after a missed progesterone-only pill for 48 hours. If the missed pill is forgotten for 24 hours, taking two pills at once may be necessary, but in this instance, as the missed pill has already been taken, that suggestion is incorrect.

progesterone Only Pill: What to Do When You Miss a Pill

The progesterone only pill (POP) has simpler rules for missed pills compared to the combined oral contraceptive pill. It is important to note that the rules for the two types of pills should not be confused. The traditional POPs (Micronor, Noriday, Norgeston, Femulen) and Cerazette (desogestrel) have the following guidelines for missed pills:

– If the pill is less than 3 hours late, no action is required, and you can continue taking the pill as normal.
– If the pill is more than 3 hours late (i.e., more than 27 hours since the last pill was taken), action is needed.
– If the pill is less than 12 hours late, no action is required, and you can continue taking the pill as normal.
– If the pill is more than 12 hours late (i.e., more than 36 hours since the last pill was taken), action is needed.

If a woman requests it, the combined oral contraceptive pill can be prescribed 6 weeks after giving birth, even if she is breastfeeding. However, it is important to note that she can still become pregnant as early as day 21 postpartum. Therefore, if she has had unprotected sex during this time, a pregnancy test should be conducted before prescribing the pill.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Treatment Options for Vulval Cancer: Simple Vulvectomy and Bilateral Inguinal Lymphadenectomy

Vulval cancer is a rare form of cancer that accounts for less than 1% of cancer diagnoses. The labia majora are the most common site, followed by labia minora. Squamous cell carcinoma is the most common type of vulval cancer, with carcinoma-in-situ being a precursor lesion that does not invade through the basement membrane. Risk factors for developing vulval cancer include increasing age, exposure to HPV, vulval lichen sclerosus et atrophicus, smoking, and immunosuppression.

Patients may present with symptoms such as itching, pain, easy-contact bleeding of the vulva, changes in vulval skin, or frank ulcers/masses. The first lymph node station for metastases is the inguinal group. Surgery is the primary treatment for vulval cancer, with a simple vulvectomy and bilateral inguinal lymphadenectomy being the usual surgery performed, even in the absence of clinically palpable groin lymph nodes.

Radiotherapy is commonly used before and/or after surgery depending on the stage of the disease, but it is not curative and would not be offered in isolation to an otherwise healthy patient. Chemotherapy is not usually used as a primary treatment but is offered in disseminated malignancy. Wide local excision is only used for lesions less than 2 cm in diameter with a depth of less than 1 mm. Lesions larger than this require vulvectomy and lymph node clearance due to the risk of metastasis.

In conclusion, a simple vulvectomy and bilateral inguinal lymphadenectomy are the mainstay of treatment for vulval cancer, with radiotherapy and chemotherapy being used in certain cases. Early detection and treatment are crucial for improving outcomes in patients with vulval cancer.

Patients experiencing secondary dysmenorrhoea should be referred to gynaecology for further investigation as it is often associated with underlying pathologies such as endometriosis, adenomyosis, fibroids, or pelvic inflammatory disease. While the combined oral contraceptive pill may provide relief, it is important to determine the root cause first. Fluoxetine is not appropriate for managing secondary dysmenorrhoea, as it is used for premenstrual dysphoric disorder. Intra-uterine devices may actually cause secondary dysmenorrhoea and should not be used. Tranexamic acid is not indicated for the management of secondary dysmenorrhoea, but rather for menorrhagia.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

Anorexia as a Cause of Secondary Amenorrhoea

This young woman is experiencing secondary amenorrhoea, which is the absence of menstrual periods for at least three months after previously having regular cycles. Her low BMI and weight loss suggest that anorexia is the most likely cause of her amenorrhoea. Anorexia is an eating disorder characterized by a distorted body image and an intense fear of gaining weight, leading to severe calorie restriction and weight loss.

In this case, the anorexia has likely caused a hypogonadotropic hypogonadism, which is a condition where the pituitary gland fails to produce enough hormones to stimulate the ovaries to produce estrogen. This hormonal imbalance can lead to a range of symptoms, including amenorrhoea, infertility, and osteoporosis.

It is important to address the underlying cause of secondary amenorrhoea, as it can have long-term health consequences. Treatment for anorexia may involve a combination of therapy, nutritional counseling, and medication. Once the underlying cause is addressed, menstrual cycles may resume, but it may take several months for regular cycles to return.

If a cervical smear is inadequate, it is recommended to repeat the test within 3 months. This is the correct course of action for the patient in question, as her routine smear was deemed inadequate. Referral for colposcopy is not necessary at this stage, as it is only indicated if there are two consecutive inadequate smears that are 3 months apart. Waiting for 3 years to repeat the smear would not be appropriate, as this is the interval for routine recall for a patient of her age. Similarly, waiting for 6 or 12 months to repeat the smear would not be appropriate, as these timeframes are only indicated for specific circumstances such as testing for cure following treatment or if the most recent smear was hrHPV positive without cytological abnormalities.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Causes of postmenopausal Bleeding: Understanding the Different Aetiologies

postmenopausal bleeding (PMB) can be a concerning symptom for women, and it is important to understand the different causes that may be responsible. One of the most common causes is vaginal atrophy, which occurs due to a decrease in oestrogen levels after menopause. This can lead to thinning and drying of the vaginal mucosa, as well as other symptoms such as vaginal dryness and an increased risk of urinary tract infections. Treatment options include non-hormonal approaches such as lubricants and moisturisers, as well as hormonal treatments like topical preparations or systemic oestrogen replacement.

Another potential cause of PMB is endometrial hyperplasia, which involves abnormal proliferation of the endometrium and is associated with an increased risk of endometrial cancer. While this is not the most common cause of PMB, ruling it out is important in order to identify any potential issues. Endometrial cancer itself is also a significant concern, with a 10% probability of being the cause of PMB. Urgent referral to a gynaecology outpatient is necessary to exclude this possibility.

Cervical cancer is not typically the cause of PMB, but it is important to discuss the cervical cancer screening programme with patients and any history of abnormal smears. Finally, the use of hormone replacement therapy (HRT) can also trigger menstruation and lead to PMB, although this is not the most common cause. By understanding these different aetiologies, healthcare providers can better diagnose and treat PMB in their patients.

The only accurate statement among the given options is that the intrauterine copper device is a safe contraceptive option for transgender males. This is because it is non-hormonal and does not interfere with testosterone therapy, although it may worsen menstrual bleeding. Condoms are also a viable option, but not the only safe one. Testosterone therapy does not prevent pregnancy and can even cause birth defects if the patient becomes pregnant. The combined oral contraceptive pill and vaginal ring are not recommended as they contain estrogen, which can counteract the effects of testosterone therapy. However, progesterone-only methods such as injections, the intrauterine system, and the progesterone-only pill are suitable options.

Contraceptive and Sexual Health Guidance for Transgender and Non-Binary Individuals

The Faculty of Sexual & Reproductive Healthcare has released guidance on contraceptive choices and sexual health for transgender and non-binary individuals. The guidance emphasizes the importance of sensitive communication and offering options that consider personal preferences, co-morbidities, and current medications or therapies.

For individuals engaging in vaginal sex where there may be a risk of pregnancy and/or sexually transmitted infections, condoms and dental dams are recommended. Cervical screening and human papillomavirus vaccinations should also be offered to sexually active individuals with a uterus. Those engaging in anal sex and rimming should be advised of the risk of hepatitis A & B and offered vaccinations. Individuals at risk of HIV transmission should be advised of the availability of pre-exposure prophylaxis and post-exposure prophylaxis as required.

For patients seeking permanent contraception, a fallopian tube occlusion or a vasectomy may be the most appropriate solution and neither would be affected by hormonal therapy. Testosterone therapy does not provide protection against pregnancy, and oestrogen-containing regimes are not recommended in patients undergoing testosterone therapy. Progesterone-only contraceptives are considered safe, and the intrauterine system and injections may also suspend menstruation. Non-hormonal intrauterine devices do not interact with hormonal regimes but can exacerbate menstrual bleeding.

In patients assigned male at birth, there may be a reduction or cessation of sperm production with certain therapies, but the variability of effects means they cannot be relied upon as a method of contraception. Condoms should be recommended in those patients engaging in vaginal sex wishing to avoid the risk of pregnancy. Emergency contraception may be required in patients assigned female at birth following unprotected vaginal intercourse, and either of the available oral emergency contraceptive options may be considered. The non-hormonal intrauterine device may also be an option, but it may have unacceptable side effects in some patients.

Overall, the guidance stresses the importance of individualized care and communication in contraceptive and sexual health decisions for transgender and non-binary individuals.

The contraceptive patch regime involves wearing one patch per week for three weeks, followed by a patch-free week. This method is gaining popularity due to its flexibility, as the patch can be changed up to 48 hours late without the need for backup contraception. Additionally, the patch’s transdermal absorption eliminates the need for extra precautions during episodes of vomiting or diarrhea. Similar to the pill, this method involves three weeks of contraceptive use followed by a one-week break, during which the woman will experience a withdrawal bleed.

The Evra patch is the only contraceptive patch that is approved for use in the UK. The patch cycle lasts for four weeks, during which the patch is worn every day for the first three weeks and changed weekly. During the fourth week, the patch is not worn, and a withdrawal bleed occurs.

If a woman delays changing the patch at the end of week one or two, she should change it immediately. If the delay is less than 48 hours, no further precautions are necessary. However, if the delay is more than 48 hours, she should change the patch immediately and use a barrier method of contraception for the next seven days. If she has had unprotected sex during this extended patch-free interval or in the last five days, emergency contraception should be considered.

If the patch removal is delayed at the end of week three, the woman should remove the patch as soon as possible and apply a new patch on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed.

If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for seven days following any delay at the start of a new patch cycle. For more information, please refer to the NICE Clinical Knowledge Summary on combined hormonal methods of contraception.

The risk of rupture is higher in ectopic pregnancies that are located in the isthmus of the fallopian tube. This is because the isthmus is not as flexible as other locations and cannot expand to accommodate the growing embryo/fetus. It should be noted that ectopic pregnancies can occur in various locations, including the ovary, cervix, and even outside the reproductive organs in the peritoneum.

Understanding Ectopic Pregnancy: The Pathophysiology

Ectopic pregnancy is a medical condition where the fertilized egg implants outside the uterus, usually in the fallopian tube. According to statistics, 97% of ectopic pregnancies occur in the fallopian tube, with most of them happening in the ampulla. However, if the implantation occurs in the isthmus, it can be more dangerous. The remaining 3% of ectopic pregnancies can occur in the ovary, cervix, or peritoneum.

During ectopic pregnancy, the trophoblast, which is the outer layer of the fertilized egg, invades the tubal wall, leading to bleeding that may dislodge the embryo. The natural history of ectopic pregnancy involves three possible outcomes: absorption, tubal abortion, or tubal rupture.

Tubal abortion occurs when the embryo dies, and the body expels it along with the blood. On the other hand, tubal absorption occurs when the tube does not rupture, and the blood and embryo are either shed or converted into a tubal mole and absorbed. However, if the tube ruptures, it can lead to severe bleeding, shock, and even death.

In conclusion, understanding the pathophysiology of ectopic pregnancy is crucial in diagnosing and managing this potentially life-threatening condition. Early detection and prompt treatment can help prevent complications and improve outcomes.

To manage unscheduled bleeding, which is a common side effect of Nexplanon, a 3-month course of the combined oral contraceptive pill may be prescribed. This will not only provide additional contraception but also make periods lighter and more regular. Prescribing a progesterone-only pill is not recommended as it can also cause irregular bleeding. A single dose of intramuscular methotrexate is not appropriate as the patient is not showing any symptoms of an ectopic pregnancy. Urgent referral for endometrial cancer is also not necessary as the patient’s age and symptoms suggest that the bleeding is most likely due to the contraceptive implant.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progesterone hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

This question involves two components. Firstly, the lady in question is seven weeks postpartum and has had unprotected intercourse after day 21, putting her at risk of pregnancy. Therefore, she must have a pregnancy test before receiving any form of contraception. Secondly, the safety of the combined oral contraceptive pill (COCP) at 7 weeks postpartum is being considered. While the COCP is contraindicated for breastfeeding women less than 6 weeks postpartum, this lady falls into the 6 weeks – 6 months postpartum category where the benefits of prescribing the COCP generally outweigh the risks. Therefore, it would be suitable to prescribe the COCP for her. It is important to note that even if a woman is exclusively breastfeeding, the lactational amenorrhea method (LAM) is only effective for up to 6 months postpartum. Additionally, while the progesterone only pill is a good form of contraception, it is not necessary to recommend it over the COCP in this case.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

The appropriate technique to treat cervical intraepithelial neoplasia (CIN2 or CIN3) is urgent large loop excision of the transformation zone (LLETZ). Cryotherapy may also be considered as an alternative. Offering the HPV vaccination is not a suitable option for individuals who have already been diagnosed with CIN2 or CIN3. A repeat cervical smear within 3 months may be offered if the high-risk human papillomavirus (hrHPV) test result is unavailable or cytology is inadequate. Routine referral to gynaecology is not necessary as the patient would already be under the care of the colposcopy service.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The addition of progesterone to hormone replacement therapy (HRT) has been found to raise the risk of breast cancer. It is worth noting that taking low doses of progesterone alone, without oestrogen, does not seem to have the same effect on breast cancer risk. If used for less than 10 years, oestrogen-only HRT does not appear to increase the likelihood of developing breast cancer. However, it does increase the risk of endometrial cancer and should be avoided unless the patient has had a hysterectomy.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

For women with atypical endometrial hyperplasia who are postmenopausal, it is recommended to undergo a total hysterectomy with bilateral salpingo-oophorectomy to prevent malignant progression. A total hysterectomy alone is not sufficient for postmenopausal women. It is also not recommended to undergo a bilateral salpingo-oophorectomy without removing the endometrium. A watch and wait approach is not advisable due to the potential for malignancy, and radiotherapy is not recommended as the condition is not yet malignant.

Endometrial hyperplasia is a condition where the endometrium, the lining of the uterus, grows excessively beyond what is considered normal during the menstrual cycle. This abnormal proliferation can lead to endometrial cancer in some cases. There are four types of endometrial hyperplasia: simple, complex, simple atypical, and complex atypical. Symptoms of this condition include abnormal vaginal bleeding, such as intermenstrual bleeding.

The management of endometrial hyperplasia depends on the type and severity of the condition. For simple endometrial hyperplasia without atypia, high dose progestogens may be prescribed, and repeat sampling is recommended after 3-4 months. The levonorgestrel intra-uterine system may also be used. However, if atypia is present, hysterectomy is usually advised.

Stages of Endometrial Carcinoma: TNM Classification Explained

Endometrial carcinoma is a type of cancer that affects the lining of the uterus. The TNM classification system is used to describe the extent of the cancer and guide treatment decisions. Here are some common stages of endometrial carcinoma:

T3a N0 M0: This stage describes endometrial carcinoma that involves the uterine serosa or adnexae, but has not spread to lymph nodes or other organs.

T3b N0 M0: This stage describes endometrial carcinoma that involves the vagina or parametrial tissues, but has not spread to lymph nodes or other organs.

T1a N0 M0: This stage describes endometrial carcinoma that is confined to the endometrium or has invaded less than half of the myometrium, without lymph node or distal metastases.

T1b N0 M0: This stage describes endometrial carcinoma that is confined to the uterus but has invaded more than half of the myometrium, without lymph node or distal metastases.

T2 N0 M0: This stage describes endometrial carcinoma that involves the cervix but has not spread beyond the uterus, without lymph node or distal metastases.

Understanding the stage of endometrial carcinoma is important for determining the best treatment options and predicting outcomes.

The addition of a progesterone to HRT raises the likelihood of developing breast cancer, making this the accurate response.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Hysterectomy is the most effective treatment for menorrhagia caused by large fibroids, which are benign tumors of smooth muscle that can grow in response to hormones. Risk factors for fibroids include obesity, early menarche, African-American origin, and a family history of fibroids. Symptoms of fibroids include heavy periods, anemia, abdominal discomfort, and pressure symptoms. Diagnosis is made through pelvic ultrasound. Medical management with NSAIDs or tranexamic acid can be tried first, but if it fails, surgical management is necessary. Uterine-sparing surgeries like myomectomy or uterine artery embolization can be considered for women who want to preserve their fertility, but hysterectomy is the definitive method of treatment for women who have completed their family or have severe symptoms. The levonorgestrel intrauterine system is not recommended for women with large fibroids causing uterine distortion. Mefenamic acid is less effective than tranexamic acid for fibroid-related menorrhagia. Myomectomy is not a definitive method of management as fibroids can recur. Uterine artery embolization is an option for women who want to preserve their uterus but not their fertility, but its effect on fertility and pregnancy is not well established.

If two consecutive samples are deemed inadequate during cervical cancer screening, the correct course of action is to refer the patient for colposcopy. Repeating the smear in 1 or 3 months is not appropriate as two inadequate samples have already been taken. Requesting hrHPV testing from the laboratory is also not useful if the sample is inadequate. Referring the patient to gynaecology is not necessary, and instead, a referral for colposcopy should be made.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Treatment and Management of Pelvic Inflammatory Disease

Pelvic inflammatory disease (PID) is a serious condition resulting from an ascending sexually transmitted infection, commonly caused by Chlamydia trachomatis or Neisseria gonorrhoeae. Patients with PID may present with symptoms such as chronic lower abdominal pain, dyspareunia, irregular bleeding, dysmenorrhoea, and purulent vaginal discharge. It is important to identify and treat PID promptly, as it can lead to complications such as infertility, ectopic pregnancy, and pelvic adhesion formation.

The management of PID depends on the severity of the presentation. Patients who are haemodynamically stable can be treated in the primary care setting with a single dose of ceftriaxone IM, followed by metronidazole and doxycycline for 14 days. However, patients with pyrexia, nausea and vomiting, or suspicion of a tubo-ovarian abscess or pelvic peritonitis should be admitted to hospital for IV antibiotics.

It is important to note that NICE recommends treating patients who are likely to have PID without waiting for swab results. In patients considered high-risk for gonococcal infection, who have no indication for admission to hospital for parenteral antimicrobial treatment, a single dose of ceftriaxone 1 g IM, followed by 14 days of metronidazole and doxycycline is recommended. Ofloxacin, moxifloxacin, or azithromycin should be avoided in women at high risk of a gonococcal infection due to increased resistance against quinolones.

In conclusion, early identification and prompt treatment of PID is crucial to prevent complications. Treatment should be tailored to the severity of the presentation and the patient’s risk factors.

The effectiveness of different contraceptives varies in terms of the time it takes to become effective if not started on the first day of the menstrual cycle. The intrauterine device is the only method that is instantly effective at any time during the cycle as it reduces sperm motility and survival. The progesterone only pill takes at least 2 days to work if started after day 5 of the cycle and is immediately effective if started prior to day 5. The combined oral contraceptive pill, injection, implant, and intrauterine system take 7 days to become effective and work by inhibiting ovulation, thickening cervical mucous, and preventing endometrial proliferation. Side effects of the progesterone only pill may include menstrual irregularities, breast tenderness, weight gain, and acne.

Counselling for Women Considering the progesterone-Only Pill

Women who are considering taking the progesterone-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

If a woman with stage IA cervical cancer desires to preserve her fertility, a cone biopsy with negative margins may be considered as an option. However, for women who do not wish to have children, a hysterectomy with lymph node clearance is recommended. Cisplatin chemotherapy and radiotherapy are not appropriate for this stage of cervical cancer, while laser ablation is only used for cervical intraepithelial dysplasias. Radical trachelectomy is not recommended as it may negatively impact fertility.

Management of Cervical Cancer Based on FIGO Staging

Cervical cancer management is determined by the FIGO staging and the patient’s desire to maintain fertility. The FIGO staging system categorizes cervical cancer into four stages based on the extent of the tumor’s spread. Stage IA and IB tumors are confined to the cervix, with IA tumors only visible under a microscope and less than 7 mm wide. Stage II tumors have spread beyond the cervix but not to the pelvic wall, while stage III tumors have spread to the pelvic wall. Stage IV tumors have spread beyond the pelvis or involve the bladder or rectum.

The management of stage IA tumors involves a hysterectomy with or without lymph node clearance. For patients who want to maintain fertility, a cone biopsy with negative margins can be performed, but close follow-up is necessary. Stage IB tumors are managed with radiotherapy and concurrent chemotherapy for B1 tumors and radical hysterectomy with pelvic lymph node dissection for B2 tumors.

Stage II and III tumors are managed with radiation and concurrent chemotherapy, with consideration for nephrostomy if hydronephrosis is present. Stage IV tumors are treated with radiation and/or chemotherapy, with palliative chemotherapy being the best option for stage IVB. Recurrent disease is managed with either surgical treatment followed by chemoradiation or radiotherapy followed by surgical therapy.

The prognosis of cervical cancer depends on the FIGO staging, with higher survival rates for earlier stages. Complications of treatments include standard surgical risks, increased risk of preterm birth with cone biopsies and radical trachelectomy, and ureteral fistula with radical hysterectomy. Complications of radiotherapy include short-term symptoms such as diarrhea and vaginal bleeding and long-term effects such as ovarian failure and fibrosis of various organs.

Tumour Markers: An Overview

Tumour markers are substances produced by cancer cells or normal cells in response to cancer. They can be used to aid in the diagnosis, monitoring, and treatment of cancer. Here are some commonly used tumour markers and their applications:

CA125: This marker is used to detect ovarian cancer. It should be tested if a woman has persistent abdominal bloating, early satiety, pelvic or abdominal pain, increased urinary urgency or frequency, or symptoms consistent with irritable bowel syndrome. If CA125 is raised, the patient should be referred for a pelvic/abdominal ultrasound scan.

AFP: Elevated AFP levels are associated with hepatocellular carcinoma, liver metastases, and non-seminomatous germ-cell tumours. It is also measured in pregnant women to screen for neural-tube defects or genetic disorders.

CA15-3: This marker is used to monitor the response to treatment in breast cancer. It should not be used for screening as it is not necessarily raised in early breast cancer. Other causes of raised CA15-3 include liver cirrhosis, hepatitis, autoimmune conditions, and benign disorders of the ovary or breast.

CA19-9: This marker is commonly associated with pancreatic cancer. It may also be seen in other hepatobiliary and gastric malignancies.

CEA: CEA is commonly used as a tumour marker for colorectal cancer. It is not particularly sensitive or specific, so it is usually used to monitor response to treatment or detect disease recurrence.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Tranexamic acid is the recommended first-line non-hormonal treatment for menorrhagia, particularly for this patient who is trying to conceive. The contraceptive pill and IUS are not suitable options, and endometrial ablation is not recommended for those who wish to have children in the future. As the patient’s periods are painless, mefenamic acid is not necessary. Tranexamic acid is an anti-fibrinolytic that prevents heavy menstrual bleeding by inhibiting plasminogen activators. This treatment aligns with the guidelines set by NICE for managing heavy menstrual bleeding.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

Management of Unprovoked Vulvodynia: Medications, Referrals, and Other Modalities

Unprovoked vulvodynia is a chronic pain syndrome characterized by chronic vulvovaginal pain lasting at least three months, without identifiable cause. The pain can be localized or generalized, has no triggers, and cannot be provoked by light touch on examination. In addition, there is associated dyspareunia. The intensity of the pain and the impact on the patient varies greatly between cases. The mainstay of first-line treatment is pain-modifying medication such as amitriptyline, an oral tricyclic antidepressant medication, which is also used in the management of depression, migraines, and chronic pain. However, if an adequate trial of amitriptyline fails to improve symptoms or if the side-effects are not tolerated by the patient, then gabapentin or pregabalin can be offered as second line. Other modalities that should be considered in the management of unprovoked vulvodynia include cognitive behavioural therapy, acupuncture, and pelvic floor exercise training. Severe unprovoked vulvodynia that persists despite the above measurements should be dealt with in secondary care by the pain team. Referral to the Gynaecology team is unnecessary unless there are concerning factors in the history or examination to point towards causes like carcinoma, sexually transmitted infections, or chronic inflammatory skin conditions.

Ectopic Pregnancy: Sites and Symptoms

Ectopic pregnancy is a condition where the fertilized egg implants outside the uterine cavity. The most common site for ectopic implantation is the Fallopian tube, particularly the ampullary region, accounting for 97% of cases. Symptoms include 4-8 weeks of amenorrhea, abdominal pain, vaginal bleeding, and signs of shock associated with rupture. Shoulder tip pain may also occur due to irritation of the phrenic nerve. Diagnosis is made through measurement of β-human chorionic gonadotrophin and ultrasound scan of the abdomen, with laparoscopic investigation as the definitive method. Treatment involves removal of the pregnancy and often the affected tube via laparoscopy or laparotomy.

Other sites for ectopic pregnancy include the peritoneum or abdominal cavity, which accounts for 1.4% of cases and may proceed to term. Cervical pregnancy is rare, accounting for less than 1% of cases. Ovarian pregnancy occurs in 1 in 7000 pregnancies and accounts for 0.5-3% of all ectopic pregnancies. The broad ligament is an uncommon site for ectopic pregnancies due to its poor vascularity.

The patient’s amenorrhea and galactorrhea are caused by hyperprolactinemia, which requires initial management to exclude hypothyroidism, chronic renal failure, and pregnancy as underlying causes. A CT scan is not necessary in this scenario. However, after excluding primary hypothyroidism and chronic renal failure, formal visual field testing can be done to investigate potential changes in keeping with a pituitary adenoma. An MRI head can also be done to look for a pituitary adenoma. Although a mammogram is not relevant in this case, the patient should still undergo breast screening. If the discharge were bloody, a mammogram would be necessary to rule out breast carcinoma.

Diagnostic Tests for Abdominal Pain in Women of Childbearing Age

Abdominal pain in women of childbearing age requires a thorough diagnostic workup to rule out gynaecological emergencies such as ectopic pregnancy. The following diagnostic tests should be considered:

1. Pregnancy test (beta-human chorionic gonadotrophin (β-hCG)): This test should be the first step in the diagnostic workup to rule out ectopic pregnancy. A positive result requires urgent referral to the gynaecological team.

2. Full blood count: This test may indicate an ongoing infective process or other pathology, but a pregnancy test should be done first to rule out ectopic pregnancy.

3. Ultrasound of the abdomen and pelvis: Imaging may be useful in determining the cause of the pain, but a pregnancy test should be done first before considering imaging studies.

4. Urine culture and sensitivity: This test may be useful if a urinary tract infection and possible pyelonephritis are considered, but an ectopic pregnancy has to be ruled out first.

5. Erect chest X-ray: This test can show free air under the diaphragm, indicating a ruptured viscus and a surgical emergency. However, a pregnancy test should be done first to rule out ectopic pregnancy.

In conclusion, a thorough diagnostic workup is necessary to determine the cause of abdominal pain in women of childbearing age, with a pregnancy test being the first step to rule out gynaecological emergencies.

Treatment Options for Pelvic Inflammatory Disease (PID)

Pelvic inflammatory disease (PID) is a common condition caused by the ascending infection of Chlamydia or gonorrhoeae from the vagina. The symptoms include bilateral lower abdominal pain, deep dyspareunia, and abnormal bleeding or discharge. The recent British Association for Sexual Health and HIV (BASHH) guideline recommends empirical antibiotic treatment for sexually active women under 25 who have these symptoms. The treatment includes stat im ceftriaxone and a 2-week course of doxycycline and metronidazole. Intravenous therapy is indicated in severe cases.

Pelvic ultrasound scan is not necessary for the diagnosis of PID. Blood tests to check inflammatory markers and serum β-HCG are not required if the clinic history and examination suggest PID. Analgesia and observation are not sufficient for the treatment of PID. Oral antibiotics alone are not recommended for the treatment of PID.

In conclusion, PID requires prompt and appropriate treatment with broad-spectrum antibiotics. The recommended treatment options should be followed based on the severity of the disease.

If a patient was assigned male at birth and is undergoing treatment with oestradiol, GNRH analogs, finasteride or cyproterone, there may be a decrease or cessation of sperm production. However, this cannot be considered a reliable method of contraception. In the case of a trans female patient, who was assigned male at birth, hormonal treatments cannot be relied upon for contraception. There is a possibility of her female partner becoming pregnant, and therefore, barrier methods are recommended. Hormonal contraceptives are not suitable for this patient, and the copper IUD is not an option as she does not have a uterus.

Contraceptive and Sexual Health Guidance for Transgender and Non-Binary Individuals

The Faculty of Sexual & Reproductive Healthcare has released guidance on contraceptive choices and sexual health for transgender and non-binary individuals. The guidance emphasizes the importance of sensitive communication and offering options that consider personal preferences, co-morbidities, and current medications or therapies.

For individuals engaging in vaginal sex where there may be a risk of pregnancy and/or sexually transmitted infections, condoms and dental dams are recommended. Cervical screening and human papillomavirus vaccinations should also be offered to sexually active individuals with a uterus. Those engaging in anal sex and rimming should be advised of the risk of hepatitis A & B and offered vaccinations. Individuals at risk of HIV transmission should be advised of the availability of pre-exposure prophylaxis and post-exposure prophylaxis as required.

For patients seeking permanent contraception, a fallopian tube occlusion or a vasectomy may be the most appropriate solution and neither would be affected by hormonal therapy. Testosterone therapy does not provide protection against pregnancy, and oestrogen-containing regimes are not recommended in patients undergoing testosterone therapy. Progesterone-only contraceptives are considered safe, and the intrauterine system and injections may also suspend menstruation. Non-hormonal intrauterine devices do not interact with hormonal regimes but can exacerbate menstrual bleeding.

In patients assigned male at birth, there may be a reduction or cessation of sperm production with certain therapies, but the variability of effects means they cannot be relied upon as a method of contraception. Condoms should be recommended in those patients engaging in vaginal sex wishing to avoid the risk of pregnancy. Emergency contraception may be required in patients assigned female at birth following unprotected vaginal intercourse, and either of the available oral emergency contraceptive options may be considered. The non-hormonal intrauterine device may also be an option, but it may have unacceptable side effects in some patients.

Overall, the guidance stresses the importance of individualized care and communication in contraceptive and sexual health decisions for transgender and non-binary individuals.

Anatomy of the Pelvis: Palpable Bones and Structures

The pelvis is a complex structure composed of several bones and joints. In this scenario, a doctor is examining a patient and can feel a specific bone. Let’s explore the different bones and structures of the pelvis and determine which one the doctor may be palpating.

Pubis:
The pubis is one of the three bones that make up the os coxa, along with the ilium and ischium. It is the most anterior of the three and extends medially and anteriorly, meeting with the opposite pubis to form the pubic symphysis. Given the position of the doctor’s hand, it is likely that they are feeling the pubic symphysis and adjacent pubic bones.

Coccyx:
The coccyx is the lowest part of the vertebral column and is located inferior to the sacrum. It is composed of 3-5 fused vertebrae and is a posterior structure, making it unlikely to be palpable in this scenario.

Ilium:
The ilium is the most superior of the three bones that make up the os coxa. It is a lateral bone and would not be near the position of the doctor’s palm in this scenario.

Sacrum:
The sacrum is part of the vertebral column and forms the posterior aspect of the pelvis. It is formed by the fusion of five vertebrae and articulates with the iliac bones via the sacroiliac joints bilaterally. Although it is found in the midline, it is a posterior structure and would not be palpable.

Ischium:
The ischium forms the posteroinferior part of the os coxa. Due to its position, it is not palpable in this scenario.

In conclusion, the doctor is most likely palpating the pubic symphysis and adjacent pubic bones during the examination. Understanding the anatomy of the pelvis and its structures is important for medical professionals to accurately diagnose and treat patients.

According to the NICE guidelines for cervical cancer screening, if an individual tests positive for high-risk human papillomavirus (hrHPV) but receives a negative cytology report during routine primary HPV screening, they should undergo a repeat HPV test after 12 months. If the HPV test is negative at this point, they can return to routine recall. However, if they remain hrHPV positive and cytology negative after 12 months, they should undergo another HPV test after a further 12 months. If they are still hrHPV positive after 24 months, they should be referred for colposcopy if their cytology report is negative or inadequate. Therefore, the appropriate course of action in this scenario is to refer the individual for colposcopy.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Treatment Options for Cystourethrocele: Conservative and Surgical Approaches

Cystourethrocele, the descent of the anterior part of the vagina attached to the urethra and the base of the bladder, can cause disruption of the continence mechanism and stress incontinence. Conservative measures such as pelvic floor exercises, pessaries, and oestrogen therapy may be used prior to surgery or as a therapeutic test to improve symptoms. However, the surgical treatment of choice is an anterior repair, also known as anterior colporrhaphy, which involves making a midline incision through the vaginal skin, reflecting the underlying bladder off the vaginal mucosa, and placing lateral supporting sutures into the fascia to elevate the bladder and bladder neck. Posterior colpoperineorrhaphy is a procedure to surgically correct lacerations or tears in the vagina and perineum. Sacrocolpopexy and sacrospinous fixation are not relevant for this patient. Approximately 50% of patients may experience post-operative urinary retention following anterior colporrhaphy.

Understanding Polycystic Ovarian Syndrome (PCOS) and Related Conditions

Polycystic ovarian syndrome (PCOS) is a hormonal disorder that affects women of reproductive age. It is characterized by enlarged ovaries with many atretic follicles but no mature antral follicles. This leads to increased production of luteinizing hormone (LH), which stimulates the cells of the theca interna to secrete testosterone. Peripheral aromatase then converts testosterone to estrogen, which suppresses follicle-stimulating hormone (FSH) secretion and upregulates LH secretion from the adenohypophysis. This results in decreased aromatase production in granulosa cells, low levels of estradiol, and failure of follicles to develop normally.

To remember the signs and symptoms of PCOS, use the mnemonic PCOS PAL. PCOS is associated with male pattern balding (alopecia), hirsutism, obesity, hypertension, acanthosis nigricans (thickening and hyperpigmentation of the skin), and menstrual irregularities (oligo- or amenorrhea). It can also cause hypogonadotropic hypogonadism, which is characterized by impaired secretion of gonadotropins from the pituitary, including FSH and LH. This condition can be caused by various factors, such as Kallmann syndrome and GnRH insensitivity. Gonadal dysgenesis, monosomy X variant, is another condition that affects sexually juvenile women with an abnormal karyotype (45, X). It results in complete failure of development of the ovary and therefore no secondary sexual characteristics. Chronic adrenal insufficiency (or Addison’s disease) is another condition that can cause anorexia, weight loss, and hyperpigmentation of the skin in sun-exposed areas.

It is important to note that early pregnancy is not a possibility in women with PCOS who are not ovulating. Additionally, if a woman with PCOS were pregnant, she would have elevated beta human chorionic gonadotropin. Understanding these conditions and their associated symptoms can help healthcare providers diagnose and manage PCOS effectively.

Cytological examination of a cervical smear sample is only conducted if it tests positive for high risk HPV (hrHPV). If the sample is negative for hrHPV, there is no need for cytology testing.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The appropriate option for emergency contraception in this case is ulipristal, which can be prescribed up to 120 hours after unprotected sexual intercourse. Levonorgestrel, which must be taken within 72 hours, is not a suitable option. Insertion of an intrauterine device or system is also inappropriate as the patient declined invasive contraception. Mifepristone is not licensed for emergency contraception.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Differentiating Gynecologic Cancers: Understanding the Symptoms and Metastasis Patterns

When a postmenopausal woman presents with vaginal bleeding, pelvic mass, and pelvic lymphadenopathy, it is important to consider the different types of gynecologic cancers that may be causing these symptoms.

Cervical squamous cell carcinoma is the most likely diagnosis in this case, as it typically metastasizes to the pelvic lymph nodes along the iliac arteries. On the other hand, endometrial carcinoma first metastasizes to the para-aortic lymph nodes, while ovarian malignancies typically spread to the para-aortic lymph nodes and are not associated with vaginal bleeding.

Uterine leiomyosarcoma, which is the most common type of sarcoma in the female pelvis, often extends beyond the uterine serosa and may metastasize to distant organs through blood vessels. However, vaginal bleeding and pelvic lymphadenopathy are not typical features of this cancer.

Cervical adenocarcinomas, which are rare and account for about 25% of cervical cancers, are associated with human papillomavirus and prolonged exposure to exogenous estrogens, but not with smoking. Their presentation and management are similar to those of squamous cancer.

Understanding the symptoms and metastasis patterns of different gynecologic cancers is crucial in making an accurate diagnosis and providing appropriate treatment.

If paracetamol and NSAIDs have not effectively controlled symptoms of endometriosis, GnRH analogues may be used as a next step in treatment. This is the appropriate course of action for a woman presenting with symptoms of deep dyspareunia and dysmenorrhoea, along with tender nodularity on examination in the posterior vaginal fornix. As endometriosis is exacerbated by rising oestrogen levels during the luteal phase of the menstrual cycle, inducing a menopause state with GnRH analogues can help alleviate symptoms. However, it is important to note that this treatment can cause menopause-like side effects and should only be initiated by specialists after careful consideration of the potential risks and benefits. The use of combined oral contraceptive pills is not recommended in this case due to the woman’s medical history of migraine with aura. Similarly, IM ceftriaxone and PO doxycycline are not appropriate treatments as they are used to manage pelvic inflammatory disease, which presents differently and is not influenced by hormones. Intra-uterine devices are also not recommended as a treatment for endometriosis as they lack a hormonal component and can worsen symptoms.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

To manage premenstrual syndrome, it is recommended to make specific lifestyle changes such as regular exercise and consuming small, balanced meals rich in complex carbohydrates every 2-3 hours. These changes are advised by the Royal College of Obstetrics and Gynaecology as a first-line management approach. It is also suggested to quit smoking, reduce alcohol intake, maintain regular sleep patterns, and manage stress levels. Contrary to popular belief, reducing dietary fats and carbohydrates is not recommended. Additionally, prescribing diazepam is not a routine management approach and is only used in select cases where anxiety is a significant symptom. Selective serotonin reuptake inhibitors like sertraline can be used for severe premenstrual syndrome, but lifestyle changes are usually sufficient for mild symptoms that do not interfere with daily life.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Annual Monitoring for Diabetes in Women with Polycystic Ovary Syndrome

Women with polycystic ovary syndrome (PCOS) are at an increased risk of developing type 2 diabetes mellitus. Therefore, it is important to monitor these patients for diabetes. The monitoring approach depends on the patient’s risk stratification, which is determined by factors such as BMI, family history of diabetes, and personal history of gestational diabetes.

For patients with evidence of impaired glucose tolerance, defined as a fasting glucose of < 7.0 mmol/l and a 2-hour OGTT of ≥ 7.8 but < 11.1 mmol/l, dietary and weight loss advice should be given, and a repeat glucose tolerance test is indicated annually. For patients with a normal glucose tolerance test, with a BMI of < 30 kg/m2, no family history of diabetes, and no personal history of gestational diabetes, annual random fasting glucose testing is appropriate. If the result is ≥ 5.6 mmol/l, then a glucose tolerance test should be performed. For patients with a BMI of ≥ 30 kg/m2, annual glucose tolerance testing is recommended. If diabetes is suspected based on symptoms such as polyuria, polydipsia, and weight loss, a random serum glucose of ≥ 11.0 mmol/l or a fasting glucose of ≥ 7.0 mmol/l is diagnostic. In asymptomatic patients, two samples of fasting glucose of ≥ 7.0 mmol/l are adequate for diagnosis. In conclusion, annual monitoring for diabetes is important in women with PCOS to prevent complications and morbidity associated with type 2 diabetes mellitus. The monitoring approach should be tailored to the patient’s risk stratification.

Surgical Options for Ovarian Cancer with Omental Involvement

When it comes to ovarian cancer with confirmed malignancy, the first-line surgery should be a total abdominal hysterectomy with bilateral salpingo-oophorectomy. This surgery should also include the removal of any omental involvement. Adjuvant chemotherapy may also be necessary. It’s important to note that ovarian cysts in postmenopausal women should always be assumed to be malignant. If there is omental metastasis, it confirms the diagnosis of ovarian cancer and surgery should include the removal of the ovaries, tubes, uterus, and omentum.

If a patient wants to preserve the possibility of future fertility, excision of the omental metastasis and unilateral oophorectomy could be considered. However, for older patients, this is an unnecessary risk. Total abdominal hysterectomy with bilateral salpingo-oophorectomy would have been the correct approach without omental involvement. Total abdominal hysterectomy with unilateral oophorectomy could be used in younger patients to maintain hormonal balance and avoid the need for HRT. However, there is a risk for recurrence, and for this patient, the omental lesion should still be removed. It’s safer to remove the uterus as well to reduce the risk of ovarian malignancy recurrence and potential uterine malignancy.

It is safe to insert a contraceptive implant after childbirth. The manufacturer of the most commonly used implant in the UK, Nexplanon®, recommends waiting at least 4 weeks postpartum for breastfeeding women. While there is no evidence of harm to the mother or baby, it is not recommended to insert an implant during pregnancy due to potential complications. It may take some time for fertility to return after pregnancy.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progesterone hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

During pregnancy, uterine fibroids may experience growth. These fibroids are common and often do not show any symptoms. However, in non-pregnant women, they can cause menorrhagia. In early pregnancy, they grow due to oestrogen and can cause pelvic pain and pressure. If they grow too quickly and surpass their blood supply, they may undergo ‘red degeneration’. This patient’s symptoms, including pelvic pain and a history of menorrhagia, suggest that the growth of pre-existing fibroids due to oestrogen may be the cause. However, further investigation with ultrasound is necessary to confirm this diagnosis. Ectopic pregnancies are rare in the second trimester and are typically detected during routine ultrasound scans. This patient is unlikely to have an ectopic pregnancy as her first ultrasound scan would have confirmed an intrauterine pregnancy. Pelvic inflammatory disease is not the most likely cause of this patient’s symptoms as it is associated with additional symptoms such as vaginal discharge and dysuria, and the patient would likely be febrile. The growth of pre-existing fibroids due to decreased progesterone is incorrect as progesterone, like oestrogen, is increased during pregnancy. This patient does not exhibit symptoms of dysuria, renal angle tenderness, or pyrexia.

Understanding Fibroid Degeneration

Uterine fibroids are non-cancerous growths that can develop in the uterus. They are sensitive to oestrogen and can grow during pregnancy. However, if the growth of the fibroids exceeds their blood supply, they can undergo a type of degeneration known as red or ‘carneous’ degeneration. This condition is characterized by symptoms such as low-grade fever, pain, and vomiting.

Fortunately, fibroid degeneration can be managed conservatively with rest and analgesia. With proper care, the symptoms should resolve within 4-7 days.

TVUS is the recommended initial investigation for PMB, unless there are contraindications. This is because it provides the most accurate measurement of endometrial thickness, which is crucial in determining if the bleeding is due to endometrial cancer.

Understanding Postmenopausal Bleeding

Postmenopausal bleeding refers to vaginal bleeding that occurs after a woman has gone 12 months without a menstrual period. While most cases do not involve cancer, it is important to rule out this possibility in all women. The most common cause of postmenopausal bleeding is vaginal atrophy, which occurs due to a reduction in estrogen following menopause. Other causes include hormone replacement therapy, endometrial hyperplasia, endometrial cancer, cervical cancer, ovarian cancer, and vaginal cancer.

To investigate postmenopausal bleeding, women over the age of 55 should undergo an ultrasound within two weeks to check for endometrial cancer. If referred on a cancer pathway, a transvaginal ultrasound is the preferred method of investigation. Treatment options depend on the underlying cause of the bleeding. For vaginal atrophy, topical estrogen and lifestyle changes can help alleviate symptoms, while HRT may also be used. If the bleeding is due to a specific type of HRT, switching to a different preparation may be helpful. In cases of endometrial hyperplasia, dilation and curettage may be necessary to remove excess tissue.

Overall, it is important for women experiencing postmenopausal bleeding to seek medical attention and undergo appropriate testing to rule out any serious underlying conditions.

Common Vaginal Infections and Their Symptoms

Vaginal infections can be caused by various organisms and can present with different symptoms. Here are some common vaginal infections and their symptoms:

1. Candida albicans: This fungal infection can cause candidiasis, which presents with a thick, cottage-cheese yellowish discharge and pain upon urination. Treatment involves antifungal medication.

2. Normal discharge: A normal vaginal discharge is clear and mucoid, without smell or other concerning symptoms.

3. gonorrhoeae: This sexually transmitted infection caused by Neisseria gonorrhoeae can cause a thick green-yellow discharge, painful urination, and bleeding between periods.

4. Chlamydia: This common sexually transmitted infection is often asymptomatic but can eventually cause pain upon urination, vaginal/penile discharge, and bleeding between periods.

5. Bacterial vaginosis: This infection is caused by an overgrowth of bacteria in the vagina and presents with a grey, watery discharge with a fishy odor. Treatment involves antibiotics and topical gels or creams.

It is important to seek medical attention if you experience any concerning symptoms or suspect a vaginal infection.

Surgical management is recommended for all ectopic pregnancies with a foetal sac larger than 35mm or a serum B-hCG level exceeding 5,000 IU/L, as per NICE guidelines. Foetal sacs larger than 35mm are at a higher risk of spontaneous rupture, making expectant or medical management unsuitable. The size of the foetal sac is measured using transvaginal ultrasound. Detection of a foetal heartbeat on transvaginal ultrasound requires urgent surgical management. A history of pelvic inflammatory disease is not an indication for surgical management, although it is a risk factor for ectopic pregnancy. Serum HCG levels between 1,500IU/L and 5,000 IU/L may be managed medically if the patient can return for follow-up and has no significant abdominal pain or haemodynamic instability. A septate uterus is not an indication for surgical management of ectopic pregnancy, but it may increase the risk of miscarriage.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

During pregnancy, fibroid degeneration can occur and may cause symptoms such as low-grade fever, pain, and vomiting.

If the ultrasound scan does not show any signs of inflammation in the appendix, it is unlikely that the patient has appendicitis.

Since the patient has fibroids in her uterus, she is at risk of experiencing fibroid degeneration, which is a common complication during pregnancy. Symptoms of fibroid degeneration may include fever, pain, and vomiting.

The absence of vaginal bleeding makes it unlikely that the patient is experiencing a threatened miscarriage.

While ovarian torsion can cause pain and vomiting, it typically occurs in patients with risk factors such as ovarian cysts or ovarian enlargement.

Understanding Fibroid Degeneration

Uterine fibroids are non-cancerous growths that can develop in the uterus. They are sensitive to oestrogen and can grow during pregnancy. However, if the growth of the fibroids exceeds their blood supply, they can undergo a type of degeneration known as red or ‘carneous’ degeneration. This condition is characterized by symptoms such as low-grade fever, pain, and vomiting.

Fortunately, fibroid degeneration can be managed conservatively with rest and analgesia. With proper care, the symptoms should resolve within 4-7 days.

To ensure maximum safety when switching from a traditional POP to COCP, it is recommended to use barrier contraception for 7 days while starting the combined oral contraceptive. This is the standard duration of protection required when starting this medication outside of menstruation. It is not necessary to use barrier contraception for 10 or 14 days, as the standard recommendation is 7 days. Using barrier contraception for only 3 days is too short, as it is the duration recommended for starting a traditional progesterone-only pill. While there may be some protection, it is still advisable to use additional contraception for 7 days to prevent unwanted pregnancy.

Special Situations for Combined Oral Contraceptive Pill

Concurrent antibiotic use has been a concern for many years in the UK, as doctors have advised that it may interfere with the effectiveness of the combined oral contraceptive pill. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines to abandon the extra precautions previously advised during antibiotic treatment and for 7 days afterwards. The latest edition of the British National Formulary (BNF) has also been updated to reflect this guidance, although precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

When it comes to switching combined oral contraceptive pills, the BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice. The FSRH’s Combined Oral Contraception guidelines state that the pill-free interval does not need to be omitted, while the BNF advises missing the pill-free interval if the progesterone changes. Given this uncertainty, it is best to follow the BNF’s advice.

Fitz-Hugh-Curtis syndrome is characterized by hepatic adhesions, which are not present in any of the other options. Therefore, the diagnosis is based on the presence of lesions rather than just the symptoms described. This syndrome is a complication of PID that causes inflammation of the liver capsule, known as Glisson’s Capsule.

Gynaecological Causes of Abdominal Pain in Women

Abdominal pain is a common complaint among women, and it can be caused by various gynaecological disorders. To diagnose these disorders, a bimanual vaginal examination, urine pregnancy test, and abdominal and pelvic ultrasound scanning should be performed in addition to routine diagnostic workup. If diagnostic doubt persists, a laparoscopy can be used to assess suspected tubulo-ovarian pathology.

There are several differential diagnoses of abdominal pain in females, including mittelschmerz, endometriosis, ovarian torsion, ectopic gestation, and pelvic inflammatory disease. Mittelschmerz is characterized by mid-cycle pain that usually settles over 24-48 hours. Endometriosis is a complex disease that may result in pelvic adhesional formation with episodes of intermittent small bowel obstruction. Ovarian torsion is usually sudden onset of deep-seated colicky abdominal pain associated with vomiting and distress. Ectopic gestation presents as an emergency with evidence of rupture or impending rupture. Pelvic inflammatory disease is characterized by bilateral lower abdominal pain associated with vaginal discharge and dysuria.

Each of these disorders requires specific investigations and treatments. For example, endometriosis is usually managed medically, but complex disease may require surgery and some patients may even require formal colonic and rectal resections if these areas are involved. Ovarian torsion is usually diagnosed and treated with laparoscopy. Ectopic gestation requires a salpingectomy if the patient is haemodynamically unstable. Pelvic inflammatory disease is usually managed medically with antibiotics.

If there is evidence of infection or an increased risk of haemorrhage, expectant management is not a suitable option for miscarriage. In such cases, NICE recommends either medical management (using oral or vaginal misoprostol) or surgical management (including manual vacuum aspiration). In this particular case, surgical management is the only option as the patient has evidence of infection, possibly due to septic miscarriage. Syntocinon is used for medical management of postpartum haemorrhage, while methotrexate is used for medical management of ectopic pregnancy. Oral mifepristone is used in combination with misoprostol for termination of pregnancy, but it is not recommended by NICE for the management of miscarriage.

Management Options for Miscarriage

Miscarriage can be a difficult and emotional experience for women. In the 2019 NICE guidelines, three types of management for miscarriage were discussed: expectant, medical, and surgical. Expectant management involves waiting for a spontaneous miscarriage and is considered the first-line option. However, if it is unsuccessful, medical or surgical management may be offered.

Medical management involves using tablets to expedite the miscarriage. Vaginal misoprostol, a prostaglandin analogue, is used to cause strong myometrial contractions leading to the expulsion of tissue. It is important to advise patients to contact their doctor if bleeding does not start within 24 hours. Antiemetics and pain relief should also be given.

Surgical management involves undergoing a surgical procedure under local or general anaesthetic. The two main options are vacuum aspiration (suction curettage) or surgical management in theatre. Vacuum aspiration is done under local anaesthetic as an outpatient, while surgical management is done in theatre under general anaesthetic. This was previously referred to as ‘Evacuation of retained products of conception’.

It is important to note that some situations are better managed with medical or surgical management, such as an increased risk of haemorrhage, being in the late first trimester, having coagulopathies or being unable to have a blood transfusion, previous adverse and/or traumatic experience associated with pregnancy, evidence of infection, and more. Ultimately, the management option chosen should be based on the individual patient’s needs and preferences.

Although clinical features such as infrequent or absent ovulation and hyperandrogenism can suggest PCOS, NICE CKS recommends using specific diagnostic criteria. To diagnose PCOS, at least 2 out of 3 of the following criteria should be present: infrequent or no ovulation, signs of hyperandrogenism or elevated testosterone levels, and polycystic ovaries or increased ovarian volume on ultrasonography. It is important to note that a high BMI is not part of the diagnostic criteria, but signs of insulin resistance such as acanthosis nigricans may aid in diagnosis.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

Management Options for Stress Incontinence: A Case-Based Discussion

Stress incontinence is a common condition that can significantly impact a patient’s quality of life. In this scenario, a female patient has attempted lifestyle changes and pelvic floor exercises for three months with little effect. What are the next steps in management?

Duloxetine is a second-line management option for stress incontinence when conservative measures fail. It works by inhibiting the reuptake of serotonin and noradrenaline, leading to continuous stimulation of the nerves in Onuf’s nucleus and preventing involuntary urine loss. However, caution should be exercised in patients with certain medical conditions.

Continuing pelvic floor exercises for another three months is unlikely to yield significant improvements, and referral is indicated at this stage.

Intramural urethral-bulking agents can be used when conservative management has failed, but they are not as effective as other surgical options and symptoms can recur.

The use of a ring pessary is not recommended as a first-line treatment option for stress incontinence.

A retropubic mid-urethral tape procedure is a successful surgical option, but it may not be appropriate for high-risk patients who wish to avoid surgery.

In conclusion, the management of stress incontinence requires a tailored approach based on the patient’s individual circumstances and preferences.

1. The initial stage of endometrial cancer typically involves a hysterectomy and bilateral salpingo-oophorectomy.
2. Diagnosis of endometrial cancer requires an endometrial biopsy.
3. Radiotherapy is the preferred treatment over chemotherapy, especially for high-risk patients after a hysterectomy or in cases of pelvic recurrence.
4. Lymphadenectomy is not typically recommended as a routine procedure.
5. Progestogens are no longer commonly used in the treatment of endometrial cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

The patient did not respond to methotrexate treatment for ectopic pregnancy, as indicated by the βhCG levels. Additionally, there is no history of increased infertility risk. According to NICE guidelines, salpingectomy is recommended for women with tubal ectopic unless they have other infertility risk factors, such as damage to the contralateral tube. Alternatively, salpingostomy may be offered. Women who undergo salpingostomy should be informed that up to 20% may require further treatment, which could include methotrexate and/or salpingectomy.

Understanding Ectopic Pregnancy

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus. This condition is characterized by lower abdominal pain and vaginal bleeding, typically occurring 6-8 weeks after the start of the last period. The pain is usually constant and may be felt on one side of the abdomen due to tubal spasm. Vaginal bleeding is usually less than a normal period and may be dark brown in color. Other symptoms may include shoulder tip pain, pain on defecation/urination, dizziness, fainting, or syncope. Breast tenderness may also be reported.

During examination, abdominal tenderness and cervical excitation may be observed. However, it is not recommended to examine for an adnexal mass due to the risk of rupturing the pregnancy. Instead, a pelvic examination to check for cervical excitation is recommended. In cases of pregnancy of unknown location, serum bHCG levels >1,500 may indicate an ectopic pregnancy. It is important to seek medical attention immediately if ectopic pregnancy is suspected as it can be life-threatening.

Expectant management of an ectopic pregnancy is only suitable for an embryo that is unruptured, <35mm in size, has no heartbeat, is asymptomatic, and has a β-hCG level of <1,000 IU/L and declining. In this case, the woman has a small ectopic pregnancy without cardiac activity and a declining β-hCG level. Therefore, expectant management is appropriate, and the woman should be given safety netting advice and asked to return for a follow-up blood test in 48 hours. Admitting her for 12-hourly β-hCG monitoring is unnecessary, and performing a salpingectomy or salpingostomy is not indicated. Prescribing medical management is also inappropriate in this case. Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test. There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility. Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Common Causes of Vaginal Discharge: Symptoms and Treatment

Bacterial vaginosis, Trichomonas vaginalis, Candidiasis, gonorrhoeae, and Pelvic inflammatory disease are some of the most common causes of vaginal discharge in women.

Bacterial vaginosis is caused by an overgrowth of anaerobic bacteria and loss of lactobacilli in the vagina. It presents with a grey-white, thin discharge with a fishy odour and an increased vaginal pH. Metronidazole is the treatment of choice.

Trichomonas vaginalis is a sexually transmitted infection that presents with a yellow-green discharge and an erythematosus cervix with a punctate exudate.

Candidiasis is a fungal infection associated with pruritus, burning, erythema, and oedema of the vestibule. The vaginal discharge is thick, curd-like, and white.

gonorrhoeae can be asymptomatic or present with abdominal pain, mucopurulent discharge, cervicitis, dyspareunia, or abnormal bleeding.

Pelvic inflammatory disease is the result of an ascending infection and presents with dyspareunia, lower abdominal pain, menstrual irregularities, irregular bleeding, and a blood stained, purulent vaginal discharge. Cervicitis and cervical excitation are also present.

Proper diagnosis and treatment are essential to prevent complications and improve the quality of life of affected women.

Understanding Different Stages of Pelvic Organ Prolapse

Pelvic organ prolapse (POP) is a common condition among women, especially those who have given birth or gone through menopause. It occurs when the pelvic organs, such as the uterus, bladder, or rectum, descend from their normal position and bulge into the vaginal canal. The severity of POP is classified into four stages based on the distance of the prolapse from the hymen.

Stage 1 prolapse is the mildest form, where the cervix descends more than 1 cm above the hymen. Stage 2 prolapse is when the most distal prolapse is between 1 cm above and 1 cm below the level of the hymen. Stage 3 prolapse is when the prolapse extends more than 1 cm below the hymen but not completely outside the vaginal opening. Finally, stage 4 prolapse is the most severe form, where there is complete eversion of the vagina.

Another type of POP is called enterocoele or enterocele, which occurs when the small intestine descends into the lower pelvic cavity and pushes into the upper vaginal wall. This can cause discomfort, pain, and difficulty with bowel movements.

In rare cases, a condition called procidentia can occur, where the uterus and cervix protrude from the introitus, resulting in thickened vaginal mucous and ulceration. This is a severe form of POP that requires immediate medical attention.

It is important for women to be aware of the different stages of POP and seek medical advice if they experience any symptoms, such as pelvic pressure, discomfort, or difficulty with urination or bowel movements. Treatment options may include pelvic floor exercises, pessaries, or surgery, depending on the severity of the prolapse.

According to the GMC guidelines in good medical practice for individuals aged 0-18 years, it is important to disclose information regarding any abusive or seriously harmful sexual activity involving a child or young person. This includes situations where the young person is too immature to understand or consent, there are significant differences in age, maturity, or power between sexual partners, the young person’s sexual partner holds a position of trust, force or the threat of force, emotional or psychological pressure, bribery or payment is used to engage in sexual activity or keep it secret, drugs or alcohol are used to influence a young person to engage in sexual activity, or the person involved is known to the police or child protection agencies for having abusive relationships with children or young people.

Failing to disclose this information or simply prescribing contraception and waiting for a review can put both the patient and other students at the boyfriend’s school in harm’s way due to his position of trust. While informing the boyfriend or his school may breach confidentiality and not address the issue of his job and relationship, it is important to take appropriate action to protect the safety and well-being of the young person involved.

When it comes to providing contraception to young people, there are legal and ethical considerations to take into account. In the UK, the age of consent for sexual activity is 16 years, but practitioners may still offer advice and contraception to young people they deem competent. The Fraser Guidelines are often used to assess a young person’s competence. Children under the age of 13 are considered unable to consent to sexual intercourse, and consultations regarding this age group should trigger child protection measures automatically.

It’s important to advise young people to have STI tests 2 and 12 weeks after an incident of unprotected sexual intercourse. Long-acting reversible contraceptive methods (LARCs) are often the best choice for young people, as they may be less reliable in remembering to take medication. However, there are concerns about the effect of progesterone-only injections (Depo-provera) on bone mineral density, and the UKMEC category of the IUS and IUD is 2 for women under the age of 20 years, meaning they may not be the best choice. The progesterone-only implant (Nexplanon) is therefore the LARC of choice for young people.

Tumour Markers for Different Types of Cancer

Tumour markers are substances that are produced by cancer cells or by the body in response to cancer. They can be detected in blood, urine, or tissue samples and can help in the diagnosis, monitoring, and treatment of cancer. Here are some tumour markers for different types of cancer:

– Ovarian cancer: CA125 is highly suggestive of ovarian cancer.
– Colorectal cancer: CEA is a tumour marker for bowel cancer.
– Breast cancer: CA 15–3 is a tumour marker for breast cancer.
– Pancreatic cancer: CA19–9 is a tumour marker for pancreatic cancer.
– Rectal cancer: Unfortunately, there is no specific marker for rectal cancer.

It is important to note that tumour markers are not always reliable and can be elevated in non-cancerous conditions as well. Therefore, they should be used in conjunction with other diagnostic tests and clinical evaluations.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women of reproductive age, characterized by cyclic behavioral, emotional, and physical changes during the late luteal phase of the menstrual cycle. The most severe form of PMS is known as premenstrual dysphoric syndrome. The hallmark psychological changes are depression, irritability, and emotional lability, while physical manifestations include fluid retention, weight gain, and breast tenderness. Symptoms improve shortly after the onset of menses, and the syndrome is unrelated to the menstrual phase. The exact cause of PMS is unknown, but a multifactorial causation has been suggested, including decreased progesterone synthesis and increased prolactin, estrogen, aldosterone, and prostaglandin synthesis during the luteal phase. Hypoglycemia and serotonin deficiency also play a role. Severe PMS is treated with selective serotonin reuptake inhibitors. It is important to understand PMS and its symptoms to seek appropriate treatment and improve quality of life.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

If a patient with primary amenorrhea has elevated FSH/LH levels, it may indicate gonadal dysgenesis, such as Turner’s syndrome.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

Medical abortions involve the use of mifepristone followed by at least one dose of prostaglandins and can be performed at any stage of pregnancy. The preferred method is oral mifepristone followed by vaginal administration of prostaglandins, such as misoprostol. This method is particularly suitable for pregnancies up to 7 weeks gestation, as it has a lower failure rate than surgical termination. The dosing schedule and location of administration may vary, with some women choosing to undergo the procedure at home rather than in a clinic. It is important to note that IM methotrexate is not used in terminations of pregnancy, but rather in the medical management of ectopic pregnancies, as well as in the treatment of certain cancers and rheumatoid conditions. Methotrexate and vaginal misoprostol is not a common combination for medical terminations, as mifepristone is typically used instead. Oral mifepristone alone is not sufficient for medical terminations, but may be used in cervical priming for surgical abortion in cases where misoprostol is contraindicated.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progesterone) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

The topic of primary amenorrhoea is being discussed, where the patient is experiencing cyclical pain but has not had any evidence of menstruation. This eliminates certain possibilities such as mullerian agenesis and constitutional delay, which are typically painless. Turner syndrome is also unlikely as it is often accompanied by distinct physical features and health issues. Pregnancy cannot be ruled out entirely, but it is improbable given the patient’s lack of menarche and cyclical pain. Therefore, imperforate hymen is the most probable diagnosis.

Amenorrhoea refers to the absence of menstruation, which can be primary (when menarche has never occurred) or secondary (when the patient has not had periods for more than six months despite having had them in the past). Primary amenorrhoea is diagnosed if the patient has not had a period by the age of 14 without any secondary sexual characteristics, or over the age of 16 if such characteristics are present. The causes of primary amenorrhoea can include constitutional delay (when the patient is a late bloomer but has secondary sexual characteristics) or anatomical issues such as mullerian agenesis (where the patient has varying degrees of absence of female sexual organs despite developing secondary sexual characteristics).

Common Causes of Delayed Puberty

Delayed puberty is a condition where the onset of puberty is later than the normal age range. This can be caused by various factors such as genetic disorders, hormonal imbalances, and chronic illnesses. Delayed puberty with short stature is often associated with Turner’s syndrome, Prader-Willi syndrome, and Noonan’s syndrome. These conditions affect the growth and development of the body, resulting in a shorter stature.

On the other hand, delayed puberty with normal stature can be caused by polycystic ovarian syndrome, androgen insensitivity, Kallmann syndrome, and Klinefelter’s syndrome. These conditions affect the production and regulation of hormones, which can lead to delayed puberty.

It is important to note that delayed puberty does not necessarily mean there is a serious underlying condition. However, it is recommended to consult a healthcare professional if there are concerns about delayed puberty. Treatment options may include hormone therapy or addressing any underlying medical conditions.

In summary, delayed puberty can be caused by various factors and can be associated with different genetic disorders. It is important to seek medical advice if there are concerns about delayed puberty.

When an ovarian cyst ruptures, it can cause sudden and severe pain on one side of the pelvis, especially after sexual activity or strenuous exercise. During a physical exam, the lower abdomen may be tender, but there may not be any other noticeable abnormalities. An ultrasound can reveal the presence of fluid in the pelvic area. It’s important to note that ovarian or adnexal torsion can also cause similar symptoms, including sharp pain on one side, nausea, and vomiting. However, in this case, a palpable mass may be felt during a physical exam, and an ultrasound may show an enlarged ovary with reduced blood flow.

Gynaecological Causes of Abdominal Pain in Women

Abdominal pain is a common complaint among women, and it can be caused by various gynaecological disorders. To diagnose these disorders, a bimanual vaginal examination, urine pregnancy test, and abdominal and pelvic ultrasound scanning should be performed in addition to routine diagnostic workup. If diagnostic doubt persists, a laparoscopy can be used to assess suspected tubulo-ovarian pathology.

There are several differential diagnoses of abdominal pain in females, including mittelschmerz, endometriosis, ovarian torsion, ectopic gestation, and pelvic inflammatory disease. Mittelschmerz is characterized by mid-cycle pain that usually settles over 24-48 hours. Endometriosis is a complex disease that may result in pelvic adhesion formation with episodes of intermittent small bowel obstruction. Ovarian torsion is usually sudden onset of deep-seated colicky abdominal pain associated with vomiting and distress. Ectopic gestation presents as an emergency with evidence of rupture or impending rupture. Pelvic inflammatory disease is characterized by bilateral lower abdominal pain associated with vaginal discharge and dysuria.

Each of these disorders requires specific investigations and treatments. For example, endometriosis is usually managed medically, but complex disease may require surgery and some patients may even require formal colonic and rectal resections if these areas are involved. Ovarian torsion is usually diagnosed and treated with laparoscopy. Ectopic gestation requires a salpingectomy if the patient is haemodynamically unstable. Pelvic inflammatory disease is usually managed medically with antibiotics.

For non-pregnant women with vaginal thrush, the recommended first-line treatment is a single-dose of oral fluconazole. This is based on NICE guidelines for the diagnosis of vaginal candidiasis. The use of clotrimazole intravaginal pessary is only recommended if the patient is unable to take oral treatment due to safety concerns. Oral nystatin is not appropriate for this condition as it is used for oral candidiasis. While topical clotrimazole can be used to treat vaginal candidiasis, it is not the preferred first-line treatment and should only be used if fluconazole is not effective or contraindicated.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

Depo-provera is linked to an increase in weight.

If this woman is concerned about weight gain, it is best to avoid depo-provera, which is the primary injectable contraceptive in the UK. Depo-provera can cause various adverse effects, including weight gain, irregular bleeding, delayed return to fertility, and an increased risk of osteoporosis.

While some users of the combined oral contraceptive pill have reported weight gain, a Cochrane review does not support a causal relationship. There are no reasons for this woman to avoid the combined oral contraceptive pill.

The progesterone-only pill has not been associated with weight gain and is safe for use in this woman.

The intra-uterine system (IUS) does not cause weight gain in users and is a viable option for this woman.

The subdermal contraceptive implant can cause irregular or heavy bleeding, as well as progesterone-related side effects such as headaches, nausea, and breast pain. However, it is not typically associated with weight gain and is not contraindicated for use in this situation.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

Diagnosis of Fibroids: Ultrasound vs CT Scan vs MRI

Fibroids, or leiomyomatas, are common tumours of smooth muscle origin found in the uterus and cervix. They can cause symptoms such as heavy periods, dysmenorrhoea, and lower abdominal pain. Risk factors include Afro-Caribbean origin, obesity, nulliparity, and family history. Clinical examination may reveal a palpable abdominal mass or a uterus palpable on bimanual examination, but ultrasound is the preferred diagnostic tool. CT scans are reserved for complex cases, while MRI is used for localisation and characterisation of fibroids. A full blood count is also important to diagnose and treat anaemia associated with heavy periods.

According to NICE guidelines, laparoscopy is the most reliable method of diagnosing endometriosis in patients who are suspected to have the condition. Even if a transvaginal or transabdominal ultrasound appears normal, laparoscopy should still be considered. If a thorough laparoscopy is conducted and no signs of endometriosis are found, the patient should be informed that they do not have the condition and offered alternative treatment options.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

When managing a miscarriage, medical treatment typically involves administering vaginal misoprostol alone. According to the NICE miscarriage Clinical Knowledge Summary, medical management is recommended if expectant management is not suitable or if a woman continues to experience symptoms after 14 days of expectant management. Misoprostol can be given orally or vaginally. If products of conception are not expelled after medical treatment or if symptoms persist after 14 days of expectant management, manual vacuum aspiration or surgical management may be considered. However, hospitalization and observation are not usually necessary unless the patient is experiencing hemodynamic instability. In most cases, women can take misoprostol and complete the miscarriage at home. Oral methotrexate is used for medical management of ectopic pregnancy.

Management Options for Miscarriage

Miscarriage can be a difficult and emotional experience for women. In the 2019 NICE guidelines, three types of management for miscarriage were discussed: expectant, medical, and surgical. Expectant management involves waiting for a spontaneous miscarriage and is considered the first-line option. However, if it is unsuccessful, medical or surgical management may be offered.

Medical management involves using tablets to expedite the miscarriage. Vaginal misoprostol, a prostaglandin analogue, is used to cause strong myometrial contractions leading to the expulsion of tissue. It is important to advise patients to contact their doctor if bleeding does not start within 24 hours. Antiemetics and pain relief should also be given.

Surgical management involves undergoing a surgical procedure under local or general anaesthetic. The two main options are vacuum aspiration (suction curettage) or surgical management in theatre. Vacuum aspiration is done under local anaesthetic as an outpatient, while surgical management is done in theatre under general anaesthetic. This was previously referred to as ‘Evacuation of retained products of conception’.

It is important to note that some situations are better managed with medical or surgical management, such as an increased risk of haemorrhage, being in the late first trimester, having coagulopathies or being unable to have a blood transfusion, previous adverse and/or traumatic experience associated with pregnancy, evidence of infection, and more. Ultimately, the management option chosen should be based on the individual patient’s needs and preferences.